Susceptibility of microRNAs 145, 143 and 133b to epigenetic regulation in colorectal cancer cell lines; prediction and functional analysis of putative targets to associated microRNAs by Govan, Drishna
Susceptibility of microRNAs 145, 143 and 133b to 
epigenetic regulation in colorectal cancer cell lines; 















A dissertation submitted to the Faculty of Health Sciences, University of 
Witwatersrand, Johannesburg in fulfilment of the requirements for the degree of 
Master of Science in Medicine 
Supervisor: 
Dr Clem Penny 











I, Drishna Govan, declare that this dissertation is my own unaided work. It has being 
submitted for the degree of Master of Science in the Faculty of Health Sciences in 
the University of the Witwatersrand, Johannesburg. It has not been submitted before 





Drishna Govan  
 




















 Govan D, Penny C, Gibbon V and Ruff P (2010). Bioinformatic prediction of 
putative microRNA targets for further evaluation in colorectal cancer. Faculty 
of Health Sciences Research Day, University of the Witwatersrand, 
Johannesburg, Sep 22nd. 
 
 Govan D, Penny C, Gibbon V and Ruff P (2011). Bioinformatic prediction of 
putative microRNA targets for further evaluation in colorectal cancer. 15th 
Congress of South African Society of Medical Oncology (SASMO/SASCRO) 
(Sun City), Aug 24th–Aug 27th. 
 
 Govan D, Gibbon V, Ruff P and Penny C. (2012) MicroRNA target sites in 
colorectal cancer. South African Society of Biochemistry and Molecular 















Colorectal cancer (CRC) is a significant health burden maintaining its position as the 
third most diagnosed cancer in men and women worldwide. Despite improvements in 
treatments for CRC, mortality rates still remain high. Genetic instability and 
epigenetic deregulation of gene expression are instigators of CRC development, 
resulting in genotype differences which herald treatment response variability and 
unpredictability. Over the past decade and a half, microRNAs (miRNA) have 
emerged as key contributors to the perturbed proteome in cancer cells, including 
CRC. MiRNAs are small non-coding RNA molecules (consisting of approximately 22 
nucleotides) targeted to specific mRNAs through various target recognition 
mechanisms to repress protein translation or to induce mRNA degradation. Three 
miRNAs, miR-143, -145 and -133b, are most commonly downregulated in CRC and 
have been proposed as potential tumour suppressors. Although downregulation of 
these miRNAs in CRC is to a large extent unexplained, epigenetic silencing has 
been postulated as a causative regulatory mechanism. Potential epigenetic 
modulation of miRNA expression, by means of histone acetylation and DNA 
methylation, was assessed in this study by treating early (SW1116) and late stage 
(DLD1) CRC cells with the DNA demethylating agent, 5-aza-2’-deoxycytidine (5-Aza-
2’C) and the histone deacetylase (HDAC) inhibitor, Trichostatin A (TSA), 
respectively. Subsequently quantifying miRNA expression, using miRNA TaqMan® 
PCR assays for each of miR-143, -145 and -133b, revealed that while all of these 
miRNAs are susceptible to DNA demethylation in early and late stage CRC cells, the 
susceptibility to DNA demethylation is significantly pronounced in the late stage 
DLD1 cells. Conversely, histone acetylation moderately affected miRNA expression 
in early stage CRC, but with a marginal effect on the expression of miRNAs in late 
stage CRC cells. These associations have been argued to correlate with genotypic 
differences between the microsatellite stable (MSS) SW1116 cell line and the 
microsatellite instability (MSI) of the DLD1 cells.  To further evaluate the role that 
these miRNAs play in CRC development, this study utilised in silico miRNA target 
prediction tools to identify potential miRNA gene target lists. Once generated, these 
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were strategically curated and filtered to allow for the election of suitable candidates 
for functional analysis. This approach yielded three candidates, KRAS, FZD7 and 
FBXW11/ß-TrCP as the most probable targets for miR-143, -145 and -133b, 
respectively, further supported by their inverse correlations to the associated miRNA 
expression in CRC. Proteomic expression of the predicted targets assessed pre- and 
post- transfection of HET-1A cells with anti-miR™ sequences of the associated 
miRNA revealed elevated protein expression with differential subcellular protein 
localization upon miRNA inhibition. Overall this study has provided further 
understanding of the contribution of epigenetics in regulation of putative tumour 
suppressor miRNAs in CRC. Additionally, KRAS targeting by miR-143 has been 
reaffirmed, while FZD7 and FBXW11/ß-TrCP expression analysis after anti-miR-145 
and anti-miR-133b transfection, respectively, provides substantial evidence for their 
role as potential direct miRNA targets. 
Keywords: colorectal cancer (CRC), epigenetics, demethylation, histone acetylase, 
5-aza-2’-deoxycytidine, Trichostatin-A, SW1116, DLD1, miR-143, miR-145, miR-
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Chapter 1: GENERAL INTRODUCTION 
 
1.1 Colorectal cancer – a significant health burden 
 
Cancer arising in the bowels or rectum, referred to as colorectal cancer (CRC), 
persists as a health burden, being the third most diagnosed cancer worldwide.  
According to the American Cancer Society  the lifetime risk of developing CRC in the 
United States is 4.7% (1 in 21) in men and 4.4% (1 in 23) in women, with the number 
of new cases expected in the year 2016 to be approximately 134 490. The number of 
deaths expected as a result of CRC in 2016 amounts to 45 190 (American Cancer 
Society, 2015). In South Africa, according to the National Cancer Registry, 1 in 97 
men are at risk of developing CRC in their lifetime, while 1 in 162 women are at risk 
of developing the disease (CANSA, 2010). Although the incidence of CRC in South 
Africa is low in comparison to various developed countries, such as the United 
States, the mortality rate in South Africa is almost equivalent to the developed world, 
as reported in the Globocan 2012 (IARC) analysis (Figure 1.1), a project of the World 
Health Organisation. The 5 year survival rate of CRC at stage I is 90%, however this 
survival rate rapidly decreases to 10% in stage IV metastatic colon cancer, 
highlighting both, the crucial importance of early detection, and improved therapies 
targeting CRC progression. In the developed world, although the mortality rate is 
said to be declining due to increased uptake of screening methods and available 
treatments, the burden of CRC still remains significantly high (Zauber, 2015). There 
are several risk factors, of which some are not changeable, that have been identified 
in the development of CRC; these being age, a history of adenomatous polyps, a 
history of inflammatory bowel disease, a family history of CRC or adenomatous 
polyps, or an inherited genetic risk (FAP and HNPCC). Modifiable risk factors for 
CRC development include diet, physical activity and obesity, cigarette smoking and 
heavy alcohol consumption (reviewed by Haggar & Boushey, 2009). 
 
  





















Figure 1.1: Estimated Incidence, Mortality and Prevalence of 
Colorectal cancer worldwide.  (Globocan, 2012). 
 
1.2 Genetic instability in CRC 
 
CRC is known to develop in an age dependent multistep progressive manner, which 
is characterised by the accumulation of genetic mutations and epigenetic aberrations 
in response to environmental and other external factors. This process which involves 
the transformation of normal colorectal epithelium through progressive steps to form 
invasive and metastatic cancer has been termed the ‘Adenoma to Carcinoma 
Sequence’ and was proposed as a model for CRC development by Fearon and 
Vogelstein in 1990 (Figure 1.2).  This transformation process takes approximately 15 
years to progress through each step with the sequence advancing through one of 
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two distinct pathways, Chromosome Instability (CIN) and Microsatellite Instability 
(MSI).  
 
The CIN pathway, also termed microsatellite stable (MSS), represents the 
development of approximately 85% of sporadic metastatic CRC tumours (Walther et 
al., 2008). Malignant transformations occurring through the CIN pathway are 
associated with an initial loss of the tumour suppressor gene APC (adenomatous 
polyposis coli), located in chromosomal region 5q21, which is a negative regulator of 
the Wnt pathway, a crucial signalling pathway in CRC (Powell et al., 1992). Further 
genetic alterations involve mutations in the KRAS oncogene, allelic loss of the 18q 
chromosomal region containing the DCC and DCP4/SMAD4 oncogenes and as well 
a late inactivation of TP53, through an allelic loss or mutation of the 17p 
chromosomal region (Leslie et al., 2002; Vogelstein et al., 1988). The prognosis of 
CIN CRC is poor, showing the worst survival amongst CRC stage II and III patients 
(Watanabe et al., 2012).  
 
MSI (microsatellite instability) refers to the epigenetic phenotype of approximately 15 
percent of sporadic colon cancers (Kinzler & Vogelstein, 1996). The MSI phenotype 
is characterised by deficiencies in the DNA mismatch repair (MMR) pathway which is 
caused by mutation or hypermethylation of the MLH1, MSH2 or MSH6 genes 
(Peltomaki  et al., 2001). The MLH proteins are responsible for the integrity of the 
genome by correcting errors during DNA replication. Inactivation of these DNA repair 
proteins results in subtle adjustments in the DNA sequence by virtue of small 
insertions and deletions in microsatellite sequences, which are short mono- or 
dinucleotide repeat sequences. These changes in the DNA sequence cause 
frameshift mutations that ultimately alter the expression of cancer related genes (Iino 
& Simms, 2000). Lynch Syndrome or hereditary nonpolyposis colorectal cancer 
(HNPCC), a genetically inherited risk factor for CRC, develops tumours primarily 
through the MSI pathway in which the DNA mismatch-repair genes are altered by 
mutation or frameshift mutations. In contrast however, the sporadic form of MSI CRC 
develops through a pathway riddled with aberrations in DNA methylation, with the 
initial MLH1 loss attributed to silencing by CpG island promoter methylation, this 
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occurring in a separate MSI pathway called CIMP (CpG Island Methylator 
Phenotype) (Worthley & Leggett, 2010).         
    
 
Figure 1.2: Adenoma to Carcinoma Sequence Model. CRC 
progresses through multiple steps from normal epithelium to 
metastatic CRC through two pathways, CIN and MSI. Each pathway 
is characterised by key genetic and epigenetic alterations at each 
step, ultimately resulting in varied outcomes (Adapted from Hrašovec 
& Glavač, 2012). 
 
1.3 Epigenetics – the missing link 
 
The ‘Adenoma to Carcinoma’ sequence is influenced by epigenetic alterations as 
depicted in Figure 1.2. Epigenetics provides an additional dimension of gene 
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regulation to the standard gene regulatory networks in a cell, demonstrating the 
effects of the chromatin structure and the external environment on the expression of 
genes, by virtue of a process known as chromatin remodelling.  
 
Conrad Hal Waddington in 1942 first described the concept of external influences on 
gene expression and is responsible for the origin of the term epigenetics. He focused 
on epigenetics in developmental biology with the proposition that the phenotype of a 
cell was determined by the interpretation of the genotype to the environment and 
external signals, in a process termed epigenesis, thus leading to the differentiated 
array of cell types in the human body (Waddington, 1942). To date, however, 
epigenetics has evolved into a more complex and abundant field of study. A later 
definition of epigenetics was provided by Riggs et al in 1996, in which it was 
indicated that epigenetics is the study of heritable changes in gene expression 
without changes in DNA sequence (genotype). This definition is commonly cited to 
date and encompasses almost all epigenetic modifications studied thus far.  
 
1.3.1 Chromatin structure  
 
In the cell, DNA, contained in chromosomes (46 per diploid human cell), is 
maintained in the nucleus in the form of chromatin, an evolved formation which 
permits the retention of the long length of DNA within the confined dimensions of the 
nucleus. On a microscopic level, chromatin would reveal DNA wound around 
octamers of globular histone proteins to form nucleosomes (Oudet et al., 1975). 
Each octamer contains two each of four distinct core histone proteins, H2A, H2B, H3 
and H4.  There are also linker histones, H1 and H5, which are responsible for 
binding the nucleosome and locking DNA into the nucleosome structure (Van Holde, 
1988). DNA weaved between nucleosomes is referred to as chromatin. 
Approximately 147 base pairs of DNA are weaved around one nucleosome with a 50 
bp linker DNA sequence separating nucleosomes (Felsenfeld & Groudine, 2003). 
Refer to Figure 1.3 below for an illustration of the chromatin structure.  
  














Figure 1.3: Chromatin structure within the cell: A clear 
indicator of the optimised packing and folding affecting the size of 
the length of DNA stored with the cell (Felsenfeld & Groudine, 
2003). 
 
There are two defined classifications of chromatin depending on the activity at the 
chromatin region. Heterochromatin, composed of condensed chromatin, is generally 
referred to those regions that are not required to be frequently transcriptionally active 
(DNA strand less accessible). In contrast, euchromatin (expanded chromatin), are 
those regions that have a high level of transcriptional activity and require the DNA 
sequence to be easily accessible to transcription initiation machinery (Eissenberg & 
Elgin, 2014). Open chromatin states are associated with accessibility of DNA to 
transcriptional machinery, as a result of DNA de-associating from the nucleosome 
structure. Closed chromatin states involve the folding of the DNA chromatin into its 
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compact form, allowing for hindrances to transcriptional machinery (Eissenberg & 
Elgin, 2014). 
Chromatin structure is controlled in layers, of which the first level of control lies in 
those proteins involved in altering the topographical status of chromatin, without 
modifying DNA or any other components of chromatin (Phillips & Shaw, 2008). 
Although nucleosomes possess a degree of intrinsic mobility, eukaryotic cells have 
evolved a class of chromatin remodelling enzymes that are responsible for a process 
known as “nucleosome sliding” (Phillips & Shaw, 2008). This involves moving the 
nucleosome in cis along DNA to create accessible regions of DNA. Another 
mechanism involves displacing histones in trans within the nucleosome to allow for 
DNA accessibility. A key example of chromatin remodelling proteins is the SWI/SNF 
family of proteins. These proteins mobilise nucleosomes along DNA to allow for 
specific regions of DNA to be more accessible for transcription (Cairns et al., 1994; 
Tang et al., 2010). This function is executed by the proteins through utilizing the 
energy provided through ATP hydrolysis, a reaction catalysed by the enzymatic 
ATPase subunit contained within the chromatin remodelling proteins (Vignali et al., 
2000). These proteins are not randomly targeted to a nucleosome, but rather found 
to be attracted to specific regions of chromatin depending on the cell’s transcription 
requirements. It is thought that transcription activating proteins bind to these 
chromatin remodelling enzymes and facilitate access of the DNA sequence to 
transcription initiation elements (Smith & Peterson, 2005).  
1.3.2 Histone modifications 
 
Histone modifications, the next layer of chromatin control, are widely studied as key 
epigenetic contributors to gene regulation. Histone proteins are post-translationally 
modified, chemically or proteomically, on their N-terminal tail (exposed) ends, 
resulting in changes in the dynamic states of chromatin. There are approximately 
eight defined types of modifications, resulting in the establishment of a histone code, 
whereby combinations of the modifications define chromatin state and gene 
expression. Acetylation, lysine and arginine methylation, phosphorylation, 
ubiquitination, sumoylation, ADP-ribosylation, deamination and proline isomerization 
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are the most current histone modifications that have been reported (Kouzarides, 
2007). Histone modification functions are separated into two types of mechanisms. 
There are those modifications that affect the net charge of the histone resulting in 
decreased affinity for negatively charged DNA, therefore providing accessibility of 
the DNA to transcription machinery.  There are also those modifications which 
function to recruit non-histone proteins that are necessary for the relevant 
transcriptional requirement for that region (Liu et al., 2005). 
Histone acetylation is the most widely studied modification and most relevant in this 
study. Historically, the concept of histone acetylation influencing transcription was 
proposed by Vincent Allfrey in 1964. Subsequent findings identified the preference of 
acetylated core histones for transcriptionally active regions (Sealy and Chalkley, 
1978; Vidali et al.,1978; Hebbes et al., 1988).  It is now known that histones are 
acetylated at lysine (K) residues on the amino-terminal ends (tail regions) of the 
histones, neutralising the charge of the histone and therefore repelling negatively 
charged DNA, ultimately exposing the DNA to RNA polymerase to allow for 
transcription initiation. This reaction is possible through the action of histone acetyl 
transferases (HAT) which are the enzymes responsible for catalysing the transfer of 
an acetyl group to the amino (N)-terminals of lysine residues contained within the 
histones. Histone acetylation is reversible through proteins that catalyze the removal 
of the acetyl group, known as Histone deacetylases (HDACs) (Kouzarides, 2007). 
Figure 1.4 illustrates the influence of histone acetylation and deacetylation on 























Figure 1.4:  Transcriptional control of histone acetylation and 
deactylation.  The acetylation of histones by histone acetyl transferase 
(HAT) changes the chromatin structure to an open state to allow for 
transcription to initiate. Deacetylation of histones via histone 
deacetylases (HDAC) returns the chromatin to a condensed state, 
halting transcription (Margolis, 2005).  
 
1.3.3 DNA methylation 
 
DNA methylation, first proposed by Holliday in 1979 as an epigenetic event, plays a 
crucial role in mammalian development. This widely studied epigenetic mechanism 
involves the covalent addition of a methyl (-CH3) group to the C5 position of cytosine 
residues occurring in large clusters of CpG dinucleotides. These CpG dinucleotides 
are asymmetrically scattered throughout the genome resulting in genomic areas that 
are either CpG-poor or CpG-rich. The latter, known as CpG-islands, are 
predominantly found at 5’ ends (promoter regions) of approximately 60% of protein-
coding genes (Kulis & Esteller, 2010). Methylation patterns are established during 
development and are stably propagated to progeny cells during mitosis. There are 
three key enzymes known as DNA methyltransferases (DNMT) that catalyse the 
DNA methylation process via methyl transfer from the methyl donor S-adenosyl-
methionine (SAM) to the cytosine residue (Figure 1.5). DNMT1 is the enzyme 
responsible for maintenance methylation which essentially copies the methylation 
  
  10 
 
patterns of the parent strand to enable stable propagation of the methylation 
signatures (Pradhan et al., 1999). DNMT3a and DNMT3b are involved primarily in de 
novo methylation and develop the methylome during embryogenesis (Okano et al., 
1999). These enzymes serve important roles in development and normal cell 
functioning. Knockouts of either enzyme cause lethality in mice (Li et al., 1992; 
Okano et al., 1999). DNA methylation inhibits transcription by altering the 
confirmation of the promoter region, thereby preventing the binding of transcription 
factors and recruiting specific methyl-CpG binding domain proteins (MBDs) which 







Figure 1.5: Cytosine methylation.  DNA methyltransferase 
catalyses the transfer of a methyl group from the methyl donor SAM 
(S-adenosyl-methionine) to the C5 position of the cytosine residue 
(Adapted from Zakhari, 2013). 
 
1.4 Cancer epigenetics 
 
Epigenetic mechanisms are involved in fine tuning cellular processes that are critical 
for proper cell function. Aberrations in these mechanisms ultimately lead to cell 
dysfunction and are associated with diseased states, including malignant 
transformation. A global decrease in the load of 5-methylcytosine, or 
hypomethylation, is frequently recognised in cancer (Feinberg & Tycko, 2004). 
Alternatively, DNA methylation is found to be concentrated in large stretches of DNA 
in cancer cells (Frigola et al., 2006). It has been thus determined that these 
abnormal concentrations of methylated DNA is responsible for silencing of classical 
tumour suppressor genes by aberrant CpG-island-promoter hypermethylation and 
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this phenomenon frequently occurs in different cancer types (Herman et al., 1994; 
Merlo et al., 1995). This observation is also associated with the CIMP CRC 
phenotype described above.  
 
Histone modifications are another epigenetic mechanism subjected to deregulation 
in cancer.  HDAC 1, 2, 3 and 8 are overexpressed in CRC compared to normal colon 
epithelium (Weichert et al., 2008). Consequently, treatment of CRC cells with a 
histone deacetylase inhibitor (HDACi) induces anti-tumour effects by reducing 
proliferation signals and inducing apoptosis (Schwartz et al., 1998, Miriadson, 2008). 
In conjunction with global increases in acetylation of H3 and H4, histone acetylation 
at histone 3 lysine 12 (H3K12), histone 3 lysine 13 (H3K13) and histone 3 lysine 27 
(H3K27) are specifically altered in CRC (Nakazawa et al., 2012; Ashktorab et al., 
2009; Karczmarski et al., 2004).  
 
In addition to the described epigenetic alterations, microRNAs (miRNAs), which are 
non-coding RNAs with an epigenetic function, are an important pathway with 
deregulated patterns in several cancers. The molecules are further described below.  
1.5 microRNAs (miRNAs) 
 
MiRNAs are a class of short (20-22 nt), evolutionary conserved non-coding RNAs, 
found to have significant roles in cellular function by post-transcriptionally regulating 
gene expression via the RNA interference pathway. Since the discovery of the first 
miRNA, lin-4 in the nematode C.elegans in 1993, substantial research has identified 
over a thousand miRNAs in the mammalian genome (Lee et al., 1993). MiRNAs 
abundantly account for up to 5% of the human genome with the ability to regulate 
more than 30% of all mRNAs, emphasizing their immense control over gene 
expression (Friedman et al., 2009). MiRNA biogenesis occurs through two distinct 
sub-cellular steps (Figure 1.4). In the nucleus miRNA genes are transcribed by Pol II 
and Pol III to create the primary miRNA (pri-miRNA) product, which forms a stem-
loop structure with extensions at the 5’ and 3’ ends (Borchert et al., 2006; Lee et al., 
2004). Processing of the pri-miRNA into precursor miRNA (pre-miR) is catalysed by 
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the “microprocessor” protein which consists of Drosha, an RNase III endonuclease, 
and the RNA binding protein DiGeorge syndrome critical region 8 (DGCR8). Pre-
miRs contain the mature miRNA sequence in either the 5’ or 3’ side of the stem-loop 
structure (Han et al., 2004). Pre-miRs are then translocated to the cytoplasm through 
the assistance of Exportin-5 and RanGTP, whereby cytoplasmic processing of the 
pre-miR to form a duplex miRNA molecule occurs via the RNase III nuclease Dicer 
(Bohnsack et al., 2004; Zhang et al., 2002).  The miRNA duplex molecule consists of 
a passenger strand (denoted by miRNA* in Fig 1.6) and the mature miRNA strand. 
After unwinding of the duplex, the mature miRNA incorporates in the RISC (RNA-
induced silencing complex) assembly unit which incorporates the four Argonaute 
proteins (Ago 1-4) and thereafter targets mRNA through imperfect pairing (described 
in chapter 3.1) to induce translation repression or mRNA degradation (Bartel, 2004).   
 
Figure 1.6: miRNA biogenesis pathway (Sigma Aldrich, 2014) 
 
MiRNAs regulate crucial physiological processes, such as development and cellular 
processes, including cell differentiation, proliferation and apoptosis (Reviewed by 
O’Hara et al., 2009). Aberrant expression of these regulators has been associated 
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with carcinogenesis, whereby altered miRNA expression profiles have been 
identified between normal tissue and derived tumour samples, demonstrating the 
potential of several miRNAs as putative oncogenes or tumour suppressor genes 
(Hammond et al., 2006; Molnàr et al., 2008; Wiemer, 2007; Bandres et al., 2007). 
Tumour suppressor miRNAs are of particular interest in this study as their targets 
would uncover potential oncogenes of clinical significance.   
 
1.6 CRC tumour suppressor miRNAs 
 
MiRNA profiling of human CRCs has revealed several deregulated miRNAs. The 
results of these studies have identified putative tumour suppressor miRNAs that 
contribute to colorectal neoplasia. The focus of this study will be on putative tumour 
suppressor miRNAs -143, -145 and -133b. Background information is provided 
below on each of these miRNAs. 
 
Michael et al. (2003) first identified downregulation of two miRNAs, miR-145 and 
miR-143, in CRC. Subsequently, Cummins et al. (2006) then discovered over fifty 
CRC-specific differentially expressed miRNAs, which also included miR-143 and 
miR-145. Furthermore, by utilising real time PCR, Bandres et al. (2006) identified 
thirteen miRNAs with altered expression in CRC cell lines when compared to normal 
colon epithelium; wherein miR-145 was also downregulated in CRC.  
 
MiR-143 and miR-145 are cluster miRNAs possessing similar patterns of gene 
expression and are therefore commonly reported together, especially with regard to 
the tumour suppressor activity in CRC (Bauer & Hummon, 2012; Chen & Wang, 
2012; Palgliuca et al., 2012; Slaby et al., 2007). MiR-133b has also been reported to 
act as a tumour suppressor and exhibits decreased expression in CRCaccording to 
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MiR-143 and miR-145 are closely related miRNAs and are found to have low 
expression levels in many cancers, thus serving as anti-oncogenic miRNA markers 
(Akao et al., 2007; Lin et al., 2009). Their genomic loci reside 1.8kb apart on 
chromosome 5q32 and may be transcribed together in a single primary transcript. 
Proliferating cells found at the base of colon membrane crypts express low levels of 
miR-143. Moreover, an inverse relationship between miR-143 and 145 expression 
and cell proliferation has been demonstrated in DLD1 colon cancer cells (Akao et al., 
2007). Their association with cell proliferation supports their involvement in cancer. 
Functionally, miR-143 regulates differentiation of adipocytes by targeting a novel 
mitogen of the mitogen-activated protein kinase (MAPK) family, ERK5 (Esau et al., 
2004). Akao et al. (2006) also validated ERK5 targeting by miR-143 in the colon 
cancer cell line, DLD1. ERK5 signalling is propagated by external stimuli such as 
stress and growth factors, resulting in the activation of several oncogenes which 
promote cell proliferation and differentiation. Translational inhibition of the oncogene 
KRAS by miR-143 has been elucidated and provides additional evidence for the 
contribution of this miRNA to the regulation of cell growth (Chen et al., 2009). With 
regard to miR-145, a close link to carcinogenesis lies in its targeting of insulin 
receptor substrate-1 (IRS-1), a docking protein for Type 1 insulin-like growth factor 
receptor (IGF-IR), which is involved in mitogenic signalling and promoting cell 
survival (Shi et al., 2007). Downregulation of the oncogene c-Myc by the tumour 
suppressor p53 has been found to be mediated by miR-145 (Sachdeva et al., 2009).  
Interestingly, c-Myc is also a downstream target of the ERK5 signalling pathway. 
The locus for miR-133b is found on chromosome 6p12.2. MiR-133b directly targets 
the proto-oncogene MET in CRC, consequently inducing growth inhibition (Hu et al., 
2010). Downregulation of miR-133b is also associated with poor survival and 
metastasis in CRC (Akcakaya et al., 2011). Besides significant downregulation in 
CRC, miR-133b association with disease has been demonstrated in 
neurodegenerative and cardiovascular disorders (Kim et al., 2007; Sucharov et al., 
2008). A lack of current literature available on this miRNA emphasises the necessity 
for its study to elucidate the mechanism by which the miRNA contributes to CRC 
development.     
  




Owing to the tumour suppressor nature of miR-143, -145 and -133b coupled with the 
known fact that tumour suppressors are aberrantly silenced through epigenetic 
mechanisms in cancer, it is postulated here that these miRNAs are regulated in the 
same manner. Furthermore, the elucidation of miR-143, -145 and -133b gene targets 
could reveal potential oncogenes of therapeutic relevance. Consequentially, to 
understand the influence of epigenetics on the expression of potential tumour 
suppressor miRNAs (miR-145, miR-143 and miR-133b) and to elucidate potential 
miRNA targets, the following three main study objectives were derived and are 
described in the chapters to follow: 
  
Objectives:    
 
 To detect stage-specific epigenetic silencing, by means of DNA demethylation 
and histone acetylation, of the putative tumour suppressor miRNAs miR-
143, -145 and -133b, in cell lines representing distinct stages of CRC.  
 To utilise in silico miRNA target prediction tools to determine putative targets 
of miR-143, -145 and -133b. This will be accomplished using available 
bioinformatic resources and strategic filtering methodology. 
 To conduct a functional analysis of the predicted targets for each miRNA by 
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2.1.1 Regulation of miRNAs 
 
Chapter one outlined the aberrant epigenetic processes and some relevant de-
regulated miRNA profiles that characterise transformed cells. A review of the miRNA 
biogenesis process and their mode of action in regulating the expression of target 
mRNAs were detailed. Owing to the involvement of miRNAs in crucial physiological 
and cellular processes such as developmental timing control, apoptosis, cell 
proliferation and the development of organs (Bartel, 2004), coupled with the 
established fact that altered patterns of miRNA expression lead to the development 
of diseased states (Ardekani & Naeini, 2010), one can infer that miRNAs would 
require finite regulation to achieve the optimal and intricate levels of expression that 
would drive the growth of normal and healthy cells.  
Although it is known that miRNAs function to modulate the expression of various 
target genes by means of mRNA cleavage or translational repression, a process that 
is now well understood, relatively less is known of the mechanisms whereby miRNAs 
are themselves regulated. The key to studying the regulation of miRNAs lies in a firm 
understanding of the biogenesis process, previously described in chapter one, to 
identify the steps at which miRNAs are potentially regulated. 
 
Firstly, when assessing the distribution of miRNA genes across the genome, it is 
apparent that some miRNAs exist as clusters and are transcribed as longer 
polycistronic primary transcripts (Kim & Nam, 2006). The vast majority of miRNA 
genes however are located in intergenic regions or in an antisense orientation to 
protein coding genes and are transcribed as independent units (Lee & Ambros, 
2001; Lee et al., 2002). Other miRNAs that are embedded in intronic regions of 
protein-coding genes are conveniently transcribed with the protein coding gene and 
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excised by means of splicing machinery from the longer transcript (Rodriguez et al., 
2004). The genomic distribution of miRNAs was identified by Calin et al., in 2004 as 
a point of regulation, as it was found that a significant percentage (~52.5%) of 
miRNAs are located at fragile sites or at regions that are associated with cancer. 
This is of great significance when analysing the altered miRNA profiles of several 
cancers. 
 
The first assumption made when approaching the mechanism of miRNA biogenesis 
was that these small RNAs are transcribed by RNA Polymerase III, as Pol III 
transcription is responsible for the transcription of small RNAs such as tRNAs and 
U6 snRNA. A key step in discovering the realms of miRNA regulation was the finding 
that these independently transcribed miRNA genes are predominantly transcribed by 
RNA Polymerase II (Pol II) instead and that pri-miRNAs transcribed in this manner 
contained a 5’cap and poly(A) tail, key characteristics of Pol II transcription. This was 
elucidated by Lee et al., (2002) following his discovery that pri-miRNAs are several 
kilobases long and contain stretches of more than four Uracils, which would have 
terminated transcription by RNA polymerase III. This finding was validated by 
expressed sequence tag (EST) analyses in which chimaeric transcripts of miRNA 
precursor and mRNA transcripts contained poly-A tails, with the evidence of 
occasional splicing (Smalheiser, 2003). More direct evidence was obtained when it 
was shown that miR-155 and miR-172 are both poly-adenylated and spliced 
(Aukerman & Sakai, 2003). Furthermore, the insertion of a Pol II enhancer had 
induced miRNA expression as in the case of bantem RNA in Drosophila (Brennecke 
et al., 2003).   
 
Although all the advancing evidence seems to point towards miRNAs being 
predominantly transcribed by Pol II, there have also been studies indicating that 
some miRNAs are in fact transcribed by Pol III, as initially presumed. Zhou et al., 
(2005) developed a computational program as a predictive tool to discriminate and 
distinguish between Pol II, Pol III and random intergenic sequences across the 
genomes of C. elegans, H. sapiens and A. thaliana. After applying their model to 
human miRNAs of intergenic location, it was predicted that many pre-miRNA 
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sequences contained Pol II promoters and only three pre-miRNA sequences 
contained Pol III promoters. Borchert et al., (2006) validated this prediction of Pol III 
transcription of miRNAs in a study of the miRNA cluster on chromosome 19 
(C19MC), wherein it was determined that some 43 mature miRNA sequences and in 
addition 52 human miRNAs were contained within repetitive elements such as Alu 
repeats; and only Pol III was required for transcription of these miRNAs.  Although 
there are some miRNAs that are located within Alu repeats that are transcribed by 
RNA polymerase III, the reminiscence of miRNA transcription by Pol II to that of 
protein-coding gene transcription is eminent. This has allowed for the research 
direction of identifying and characterizing miRNA promoter regions. 
 
Computational programs have aided in providing information on the regulatory 
elements that are located upstream of miRNA genes (Lee et al., 2007). Methods to 
identify miRNA transcription start sites (TSS) stemmed from studies identifying 
chromatin signatures that were present at initiation sites. Trimethylation of lysine 4 
on histone 3 (H3K4me3) is a persistent modification that signifies the TSS of many, if 
not all, human genes and it seems as if this modification is restricted to the sites at 
which transcription initiates (Guenther et al., 2007; Barski et al., 2007). In addition, 
the chromatin locations of genes that are transcriptionally active are depleted of 
nucleosome activity within 100-130kb surrounding the transcriptional start site (Yuan 
et al., 2005). Using H3K4me3 as a landmark, Marson et al. (2008) took advantage of 
these findings and formulated a library of putative TSSs, revealing high confidence 
promoters for more than 80% of miRNAs experimentally validated in humans and the 
mouse. Importantly, this study allowed for the promoter regions to be mapped 
computationally to putative transcription factor binding sites. Saini et al. (2007) 
identified regulatory binding sites for transcription factors upstream of the pre-miRNA 
genomic regions and it was determined that approximately 60% of these sites were 
clustered within 1kb. These regulatory binding sites overlapped the predicted TSSs 
which were located within regions -2 and -6kb. Interestingly it was also found that 
miRNAs may possess more than one predicted TSS. The miRNA promoter regions 
were found to contain relative frequencies of several regulatory elements which 
include TATA box, TFIIB recognition, initiator elements, histone modifications and 
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CpG islands (Ozsolak et al., 2008; Corcoran et al., 2009). These regulatory features 
render miRNA promoter regions relatively indistinguishable from mRNA promoter 
regions.  
 
Many relationships between known transcription factors and miRNAs have been 
identified since. Of particular significance to carcinogenesis, c-Myc, a proto-
oncogenic transcription factor responsible for regulating genes involved in cell 
growth and apoptosis, has been found to modulate the transcriptional regulation of 
several miRNAs, most notably the oncogenic miRNA cluster miR-17-92 (O’Donnell 
et al., 2005; Chang et al., 2008). Increased expression of c-Myc in turn activates the 
expression of miR-17-92, forming a feedback loop. The tumour suppressor miR-34 is 
regulated by the p53 transcription factor (Bommer et al., 2007; Chang et al., 2007; 
Raver-Shapira et al., 2007; Tarasov et al., 2007; Corney et al., 2007). The 
deactivation of p53 results in a reduced expression of miR-34 (He et al., 2007). With 
regard to angiogenesis, miR-210 is activated upon increased expression of the heat 
inducible transcription factor (HIF), in response to hypoxic stress (Giannakakis et al., 
2007; Camps et al., 2008). MiR-145, a particular focus of the present study, had 
induced a pro-apoptotic effect dependent upon the expression of TP53. TP53 also 
activates miR-145 expression demonstrating a cell death promoting loop between 
the two (Spizzo et al., 2010). The interesting interactions between transcription 
factors and miRNAs were analysed using bioinformatics tools and it seems that 
miRNAs are inclined towards regulating transcription factors (Shalgi et al., 2007). 
Further, autoregulation and feedback loops are evident in many instances where 
transcription factors that regulate the expression of miRNAs also serve as targets of 
the miRNAs forming an autoregulation feedback loop that controls one another’s 
expression. Relevant examples here include Runx1 and miR-27a in 
megakaryopoiesis (Ben-Ami et al., 2009), c-Myb and miR-15a in haematopoiesis 
(Zhao et al., 2009) and with bearing to this study, Pitx3 and miR-133b, albeit not 
relevant in cancer (Kim et al., 2007).  
 
While miRNAs are involved in complicated regulatory, molecular and cellular 
pathways, significant gaps still exist in this field of research. What we can be certain 
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of is that miRNAs seem to be regulated by similar mechanisms to protein coding 
genes and that it can be inferred that each avenue of mRNA regulation is potentially 
involved in the regulation of miRNAs as well. Pursuant to this inference and coupled 
with the identification of CpG islands and histone modifications in miRNA promoter 
regions, the possibility of epigenetic regulation of miRNAs may not be dismissed.  
 
2.1.2 Epigenetic regulation of miRNAs    
           
The first published study targeted at investigating the effects of epigenetics on 
miRNA expression assessed the effect of histone acetylation on miRNA expression. 
The breast cancer cell line, SkBr3, was treated with the HDACi LAQ824, resulting in 
rapid alterations in miRNA expression, with the subsequent downregulation of 32 
mature miRNAs (Scott et al., 2006). Epigenetic entities (DNA methylation and 
histone modifications) work in a coordinate and cooperative manner to regulate gene 
expression and by using this premise the team of the renowned cancer epigeneticist, 
Prof. Peter A. Jones, conducted a study on the miRNA expression profile of the T24 
human bladder cancer cell line after simultaneous treatment with the DNA 
demethylating agent, 5-Aza-2’-deoxycytidine (5-Aza-2’-C) and the HDACi 4-
phenylbutyric acid (PBA); resulting in 17 out of 313 miRNAs being upregulated (Saito 
et al., 2006). One of the miRNAs, miR-127, was found to be integrated within a CpG 
island. Since miR-127 expression is significantly reduced in cancer cells, this 
indicated that this miRNA and putative tumour suppressor is susceptible to 
epigenetic silencing. Also, a predicted target of miR-127, the proto-oncogene BCL-6, 
was downregulated post-treatment with 5-Aza-C and PBA. Other examples of 
epigenetic modulation of miRNAs include miR-1, which was upregulated in response 
to HDACi treatments in lung cancer cells (Nasser et al., 2008). MiR-1 is encoded 
with the miR-133 cluster and miR-1, miR-133 and miR-206 (a miR-1 functional 
homologue) is significantly downregulated in several solid tumours (Hudson et al., 
2011). Moreover, in the context of colon cancer, in the HCT116 CRCcell line wherein 
the two main DNA methyltransferases DNMT1 and DNMT3b were knocked out by 
homologous recombination, 18 miRNAs were upregulated, including miR-124a, a 
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putative bona fide tumour suppressor (Lujambio et al., 2007). The silencing of miR-
124a induces the expression of the cell cycle cyclin dependent kinase 6 (CDK6) and 
subsequently the phosphorylation and thus regulation of the tumour suppressor 
protein, retinoblastoma (Rb).  It is thus evident that miRNAs respond to and are 
regulated, directly or indirectly, by epigenetic mechanisms. The expression patterns 
of miRNAs are not uniform however, showing differential expression patterns 
between different tissues or cell types. There have also been contradictory studies 
that have identified no change in miRNA expression in the lung cancer cell lines, 
A549 and NCI-H157, following treatment with epigenetic drugs (Yanaihara et al., 
2006; Diederichs et al., 2006).    
Similar to the mechanism of repression of tumour suppressor protein coding genes 
by aberrant DNA hypermethylation at promoter regions, this mechanism has been 
validated to repress the expression of several miRNAs, miR-1-1, miR-193a, miR-
137, miR-342, miR-203 and miR-34b/c, by means of hypermethylated promoter 
regions (Lujambio et al. 2009; Lujambio et al. 2008). Although it is not certain if this 
mechanism contributes to the downregulation of all tumour suppressor miRNAs in 
cancer, evidence however points to it being the likely cause. 
 In the context of this chapter, the putative CRC tumour suppressor miRNAs in 
question in this study, miR-145 and -143, have not yet been validated as being  
epigenetically silenced by aberrant DNA hypermethylation or histone modifications in 
CRC. Nevertheless, two independent studies have identified that miR-145 is 
hypermethylated at the promoter locus causing repression in prostate cancer 
(Zaman et al., 2010; Suh et al., 2011). MiR-143 has been shown to be repressed by 
DNA hypermethylation in primary blast cells containing the fusion protein MLL-AF4 in 
acute lymphoblastic leukaemia (Dou et al., 2012). This repression by DNA 
hypermethylation was not shown in MLL-AF4 negative ALL derived cells and was 
also not apparent in normal cells. At the time of the development of this project, there 
was a lack of evidence on any epigenetic regulation of miR-133b; however a recent 
finding has provided evidence of epigenetic regulation of miR-133b via promoter 
hypermethylation in CRC (Lv et al., 2015). Literature in regard to epigenetic 
alterations of miRNA expression however has revealed differential expression 
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patterns between the various cell and tissue types and stages described by finite 
regulation in a spatio-temporal manner; therefore it can be assumed that the 
epigenetic profile of cancer may evolve as the disease progresses through various 
stages.  
The aim of this chapter is to assess epigenetic alterations by means of DNA 
methylation and histone acetylation on the expression of the three putative tumour 
suppressor miRNAs in CRC cell lines. In the present study, cell lines from two 
different progressive stages of CRC were utilised to assess the stage specific 
alterations in miRNA expression post treatment with the epigenetic agents, 5-Aza-2’-
C and Trichostatin A (TSA), respectively. These drugs are described below. 
2.1.3 Epigenetic drugs 
 
2.1.3.1 5-Aza-2’–C and its use as a DNA demethylating agent 
 
5-Aza-2’-C is used as a DNA demethylating agent in this study. It is essentially an 
analogue of the naturally occurring nucleoside 2’-deoxycytidine however the carbon 
at the fifth position has been replaced by nitrogen (Refer to Figure 2.1). It functions 
as a DNA demethylating agent by incorporating into DNA and therefore binding DNA 
methyltransferase enzymes irreversibly, as it attempts to methylate the C5 position 
of the nucleoside. By sequestering the DNA methytransferase enzymes in this 
manner, it gradually results in global genome DNA hypomethylation and therefore 
reactivates genes that have previously been silenced (Christman, 2002). This has 
attracted the use of this compound as an anti-neoplastic agent. The compound was 
initially synthesised in 1964 by Pliml and Sorm and in 1968 the first sign of anti-
leukaemic activity was reported (Sorm & Vesely, 1968). It is more commonly known 
as Decitabine (trade name Dacogen) after it had been indicated for the treatment of 
Myelodysplastic syndrome and Chronic Myelomonocytic leukaemia (Kantarjian et al., 
2006). Strong anti-leukaemic activity against Acute Myeloid Leukaemia has also 
been reported for Decitabine in these preceding studies.   
 
  










Figure 2.1: Comparison of 5-Aza-2’-C to a methylated 
cytosine. A. Chemical structure of 5-Aza-2’-C: C8H12N4O4. The 
red dashed box highlights the nitrogen replacement of the carbon 
molecule at the C5 position. B. Chemical structure of methyl 
cytosine. The methyl group which is added to the cytosine in a 
CpG island is highlighted in red at the C5 position (Fenaux, 2005). 
 
2.1.3.2 Trichostatin A and its use as a histone deacetylase inhibitor 
 
TSA (as depicted by the organic structure in Figure 2.2) was initially isolated and 
described in 1975 by a group of scientists in Japan (Tsuji, 1975), as an antifungal 
antibiotic which originated from metabolites of strains of Streptomyces 
hygroscopicus. The compound is organically derived from a primary hydroxamic acid 
and has a free glycosylated hydromaxate group shown in Figure 2.2.  HDACs fall 
into 3 main families, with 18 HDACs identified to date. TSA inhibits histone 
deactylation by targeting Zn2+ dependent Class I and Class II HDACs, induces 
histone hyperacetylation and inhibits cell proliferation (Witt et al., 2009). Hydroxamic 
acids have a high affinity for biometals and TSA specifically interacts with the Zn2+ 
ion in the catalytic unit of Class I and II HDACs with a resulting inhibitory effect. TSA 
imposes its strongest inhibitory effect on HDACs 1, 2 and 3 of the Class I HDACs, 
HDAC 4, 7 and 9 of the Class IIA HDACs and HDAC 6 of the Class II B HDACs (Witt 
et al., 2009). 
  













Figure 2.2: Trichostatin A structure and targets. A. Chemical 
structure of Trichostatin A: C17H22N2O3. The hydroxamate group is 
circled in red. B. Trichostatin HDAC targets. TSA inhibits the 
activity of Class I and II HDACs with the strongest inhibitory effect 
on HDAC 1, 2, 3, 4, 6, 7 and 9. Adapted from Witt et al., (2009). 
 
2.1.4 Methods to isolate and study miRNAs 
 
The small size of miRNAs presents a challenge for amplification and subsequently 
quantitation of these RNA species. Previously, the most predominant method for 
miRNA quantitation involved the use of Northern Blots, a convenient and readily 
accessible electrophoretic and hybridization probe based technique. This method 
however eventually presented several limitations, most significantly in specificity and 
reproducibility. Large volumes of sample material are required per lane 
(approximately 5-10 mg) to detect miRNAs and therefore relatively low abundant 
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miRNAs are predominantly undetected using this method, as only one miRNA probe 
is hybridised to the blot at one time.  Also, a significant disadvantage lies in not being 
able to discriminate between miRNAs differing by one nucleotide, using the 
hybridization probes for Northern analysis. Furthermore, the nature of the experiment 
requires several assay repeats for statistical significance, yet the reproducibility of 
the method is not the most reliable due to its laborious nature and lack of automation 
(Chen et al., 2005).  
For these reasons a better method was deemed necessary for the analysis of 
miRNAs, with the specificity and reliability of PCR (polymerase chain reaction) being 
the most attractive option.  Implementing this method for miRNA analysis however 
came with its own set of challenges. Initial PCR assays for miRNA detection had 
relied on the miRNA precursor template and thus could not quantify the active 
mature miRNA. Furthermore, conventional primers for PCR are approximately the 
size of a mature miRNA strand which is 21-25 nucleotides in length. In addition, the 
stem loop structure formed by miRNA precursors do not allow for a convenient 
template for miRNA amplification. These challenges were overcome with the 
development of a miRNA PCR Assay utilizing miRNA-specific stem loop reverse 
transcription primers as depicted in Figure 2.3. In this study, reverse transcription of 
the miRNA to cDNA was achieved using miRNA-specific stem loop primers for miR-
143, -145 and -133b (Applied Biosystems). The stem-loop primers are designed to 
overcome this problem of the short mature miRNA template by specifically binding to 
the mature miRNA target and forming a miRNA-primer complex that extends at the 
5’ end of the miRNA. There are several advantages conferred by the stem looped 
structured primer;  
1) The short RT priming sequence which is annealed to the 3’ end of the miRNA has 
better specificity for discriminating between similar miRNAs and has the ability to 
discriminate single nucleotide differences in sequence.  
2) The double stranded stem loop structure prevents hybridization to the miRNA 
precursor and other longer RNA amplicons.  
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3) Base stacking in the stem region increases the stability of the miRNA and hetero-
duplexes which ultimately enhance reverse transcription efficiency for short reverse 
transcription primers (the short sequence bound the 3’ end).  
 4) When the stem loop structure unfolds, the presence of a sequence downstream 
of the miRNA extends the length of the amplicon requiring quantification. The 
resulting longer amplicon post reverse transcription is conducive to Real Time PCR 












Figure 2.3: TaqMan®  miRNA PCR Assay. In Step 1, the miRNA specific 
RT stem loop primer is shown which confers several benefits in the specificity 
and sensitivity of the subsequent reactions. After reverse transcription in Step 
1, the resulting longer amplicon is then subjected to TaqMan® PCR in Step 2, 
using miRNA specific forward and reverse primers. The forward primer at the 
5’ end of the amplicon has an added tail to increase the melting temperature 









The overall aim of this chapter is to seek clarity regarding potential epigenetic 
regulation of the three putative CRC tumour suppressor miRNAs -143, -145 and -
133b in relation to CRC. In this regard, the following objectives were defined: 
 To determine the effect of epigenetic treatments (HDAC inhibitor 
TSA and DNA demethylating agent 5-Aza-2’-C) on the viability of 
CRC cell cultures 
 To detect changes in expression levels of the miRNAs -145, -143 
and -133b upon DNA demethylation 
 To detect changes in expression of the miRNAs -145, -143 and -
133b upon inhibition of histone deacetylation 
 To detect stage-specific differences in miRNA expression after 
treatment with epigenetic treatments 
 To compare the effects of DNA demethylation versus histone 
acetylation on the expression of the miRNAs 
 
2.2 Materials & Methods 
2.2.1 Cell culture 
 
Aseptic techniques were utilised throughout the cell culture process to ensure 
prevention of contamination by means of microbacteria, fungi and mycoplasma. This 
was achieved by performing cell culture procedures under a laminar flow hood that 
was sterilised with a germicidal UV lamp when not in use. During the use of the 
hood, a fan was switched on which drew in air through a HEPA filter which ensured 
that the air was microbe free. All surfaces and gloves were periodically sterilised with 
70% v/v ethanol.  
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The two colorectal adenocarcinoma cell lines, SW1116 (ATCC CCL 233) and 
DLD1(ATCC CCL 221) were obtained from the Health Science Research Resources 
Bank (HSRRB) of the Health Science Foundation of Japan. These cell lines are 
representative of stage I and stage III (metastatic) CRC, respectively. These cell 
lines were routinely cultured in DMEM-F12 (Lonza-Biowhittaker®) culture media 
supplemented with 2% v/v and 10% 
v/v heat inactivated foetal bovine serum (FBS), 
respectively; and with 0.2% Penicillin/Streptomycin (Lonza BioWhittaker®).  
The cell lines were initially rapidly thawed from the -70°C storage facility, rinsed by 
centrifugation in sterile Phosphate-Buffered Saline (PBS) solution and then placed 
into culture. Cells were plated into cell culture flasks and placed into the 37% 
incubator supplied with 5% CO2 in air.  Cells were subcultured at 80% confluency, 
that is, when approximately 80% of the surface of the cell culture flask had been 
occupied by the dividing cells. After removing the remaining cell culture media, 
confluent SW1116 and DLD1 cell cultures were rinsed with PBS and then incubated 
with 0.25 % deactivated Trypsin/ EDTA for 5 and 3 minutes, respectively. Once in 
suspension, the cells were pelleted by centrifugation at low speed (300rpm) for 1 
minute. After removing the supernatant, the cell lines were re-suspended in fresh 
culture media and transferred to new cell culture flasks and placed in the incubator 
for subsequent cell expansion. Surpluses of the cell lines were harvested and stored 
cryogenically.  
With regards to the ethical considerations pertaining to the use of in vitro cell cultures 
for research purposes, the use of cell lines purchased from an accredited cell bank 
do not require approval from the Wits Human Research Ethics Committee (Wits 
HREC). However an ethics waiver was obtained for the study (Ref: W-CJ-090317-4). 
(Refer to Appendix A).  
2.2.2 Epigenetic drug treatments 
 
To evaluate the contribution of epigenetic modulation on the regulation of miR-143, -
145 and -133b expression in CRC, the CRC cell lines SW1116 and DLD1 were 
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subjected to epigenetic treatments involving two entities of epigenetic regulation; 
DNA methylation and histone acetylation, respectively. 
Cell cultures were starved of serum overnight to synchronise the cells in the G0 
(quiescent) phase of the cell cycle prior to drug treatment, therefore creating a 
homogenous baseline.  
To assess the effects of DNA methylation on the expression of miRNAs, cell cultures 
were treated with 5-Aza-2’-C. The DNA de-methylating agent, 5-Aza-2’-C (Sigma 
Aldrich), was dissolved at a concentration of 50mg/ml in 99% acetic acid:PBS at a 
1:1 ratio and stored at -70°C. Post thawing, 5-Aza-2’-C was added to cell culture 
media at concentrations of 1µM and 3µM, respectively.  
The stock solution of 5-aza-2'deoxytydine (50mg/mL) involved dissolving 10mg 5-
aza-2'-C in 200µL of an acetic acid (99%):PBS solvent in a 1:1 ratio. The 50mg/mL 
stock solution therefore contained 49.5% acetic acid. A 10µM stock solution was 
then created using 2.5µL of the 50mg/mL stock solution added to 50mL cell culture 
medium. The resultant acetic acid percentage reduced to 0.0025%. Further dilutions 
to 1µM and 3µM decreased the acetic acid percentage to 0.000125% and 
0.000375% respectively. At these concentrations, there is no reported effect of acetic 
acid on cell viability, gene expression or DNA methylation. Marina et al in 2010 had 
reported on the effects of acetic acid on mammalian cell culture in which it was 
determined that 0.03% of acetic acid had minimal effect on pH when cells were 
maintained at 37˚C. It was argued that this minimal effect was due to metabolising 
cells maintained at 37˚C having superior internal cellular pH control. Furthermore, 
DNA methylation has previously been documented to remain stable during pH 
changes (Ernst et al., 2008). An acetic acid control was therefore not deemed 
necessary in this experiment. No treatment controls were treated as per standard 
cell culture protocol as described above under paragraph 2.2.1. Cell cultures of the 
two cell lines were treated with 5-Aza-2’-C for 48 hours, with a daily replacement of 
the drug treatment due to the instability of the 5-Aza-2’-C compound.  
To assess the effects of histone acetylation on the expression of miRNAs, cell 
cultures were treated with TSA, a HDACi. TSA (Sigma-Aldrich), reconstituted at a 
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concentration of 5mM in dimethyl sulfoxide (DMSO) (stored at -20°C) was diluted 
down to a 1000nM stock solution. The stock solution was then added to cell culture 
media at a 300nM concentration. Following serum starvation, SW1116 and DLD1 
cell cultures were subjected to a 24 hour treatment of 300nM TSA. A DMSO (Sigma-
Aldrich) carrier control was included in the treatments, to evaluate non-specific 
effects that may be induced by DMSO itself.  Dimethyl sulfoxide (DMSO) is an 
amphipathic solvent characterised by its ability to penetrate the cell membrane. This 
property has allowed for the solvent to be used as an effective drug delivery 
molecule, owing to its ability to dissolve both polar and non-polar compounds 
(Santos et al., 2003). It is also known to have various effects on gene expression 
and therefore warrants a control sample.  
2.2.3 Cell viability 
 
Post treatment with the epigenetic treatments, both cell lines were harvested and re-
suspended in 1mL PBS. One part filtered Trypan Blue (Biorad) was added to one 
part cell suspension (in cell culture media). The mixture was allowed to react at room 
temperature for approximately 3 minutes. A drop (100µL) of the Trypan Blue/cell 
suspension was added to a haemocytometer and placed on the stage of the inverted 
bifocal microscope. Once focused on the cells, the number of viable (clear) and non-
viable (blue) cells were counted within the specified area. Cell viability was 
calculated according to the equation below: 
% viable cells = Total number of viable cells per 1 mL of aliquot    X 100 
Total number of cells per 1mL of aliquot 
 
2.2.4  MicroRNA isolation 
 
To assess the effect of the epigenetic drug treatments on the miRNAs in question 
the first step post- treatment was to isolate good quality RNA. Due to the small size 
of miRNAs and the notorious instability of RNA, it was deemed necessary to source 
an RNA extraction method that preserved the integrity of these small RNA’s. Initially, 
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homogenised cell culture lysates were subjected to the MicroRNA “Cells to Ct” kit 
from Applied Biosystems, which eliminates the RNA isolation procedure and reverse 
transcribes RNA into cDNA directly from the cell lysate (Ho et al., 2013). Although 
the elimination of the RNA extraction step is intended to prevent contamination and 
hence the degradation of RNA, low RNA yields together with high salt concentrations 
were obtained, as determined by the A260/A230 OD ratio. This negatively impacted 
RNA quality and purity and thus PCR performance, emphasizing the requirement for 
a more suitable method. For this reason the mirVana miRNA isolation kit available 
from Ambion was evaluated. 
There are two popular methods for the extraction of RNA, chemical extraction and 
solid-phase extraction, either of which is incorporated in the various commercial kits 
available for RNA extraction. Chemical extraction involves the use of a concentrated 
chaotropic salt, such as guanidinium thiocyanate, sodium acetate and 
phenol:chloroform. The chaotrope allows for the denaturing of macromolecules, such 
as DNA, RNA and proteins. After centrifugation, the acidic solution then separates 
these macromolecules into different phases. RNA remains in the aqueous upper 
phase, while proteins remain in the interphase and DNA is contained in the lower 
organic phase. RNA is precipitated out of the aqueous phase with the use of 
isopropanol or ethanol (Chomczynski & Sacchi, 2006) 
Solid-phase extraction involves the use of high salt concentrations or salt and 
alcohol mixtures to decrease the affinity of RNA for water, resulting in increased 
affinity to the solid material (glass fibre) used to precipitate the RNA (Tan and Yiap, 
2009). 
The mirVana miRNA isolation kit uses the most convenient combination of both 
methods to extract high quality RNA enriched with small RNAs. This is done by 
eliminating the steps that would compromise the extraction of small RNAs, such as 
routine alcohol precipitation and high concentrations of denaturing salts. For these 
reasons the mirVana kit was chosen as the optimal and most appropriate method to 
extract RNA suitable for this protocol.   
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Treated and control cell cultures were subjected to the miRvana miRNA isolation kit 
(Ambion). The kit provides separate procedures for the isolation of total RNA 
containing conserved small RNAs or the extraction of RNA enriched with small RNAs 
below 200 bases in size. For the purpose of this experiment, the purification of total 
RNA was followed, as miRNA with preserved integrity of the flanking regions were 
required for the procedures to follow. 
Approximately 1 x 106 cells were harvested and then lysed by adding 300-600µL of 
Lysis/Binding Solution contained within the kit. To ensure complete homogenisation, 
the lysates were vortexed briefly. The homogenates were then subjected to organic 
extraction. First, a 1/10 volume of miRNA homogenate additive was added to 
preserve the integrity of miRNAs. This was left on ice for 10 min. Then 300-600µL of 
Acid-Phenol: Chloroform was added to the homogenate, vortexed for 30-60 seconds 
and centrifuged for 5 minutes at maximum speed (10 900 x g) to separate the 
aqueous and organic phases of the mixture. After centrifugation the aqueous phase 
containing RNA was carefully removed, without disturbing the interphase (proteins) 
and lower phase (DNA), and transferred to a fresh tube. The volumes removed were 
noted and subsequently 1.25 volumes of room temperature ACS grade 100% 
ethanol were added. Exactly 700µL of the mixture was then transferred to a filter 
cartridge placed in a collection tube, and centrifuged at 10 000rpm to pass the 
mixture through the filter. The flow-through was discarded and the step repeated 
until all the ethanol/lysate mixture had passed through the filter. Subsequently, 
700µL of Wash 1 (provided in the kit) was then added to the filter and centrifuged at 
10 000rpm for 5-10 seconds. The flow-through was discarded; following which 500µL 
of Wash 2/3 was added to the filter and centrifuged. Flow-through was discarded and 
the wash step with Wash 2/3 was repeated, followed by a 1 min centrifugation at 10 
000rpm to remove any residual fluid that may have been left in the filter. The filter 
cartridges were then transferred to fresh, clean collection tubes and the RNA 
contained in the filter was eluted with 100µL of 95°C pre-warmed Elution Solution 
(contained in the kit). This was done by transferring the Elution Solution to the centre 
of the filter followed by centrifugation at 10 000rpm for 20-30 seconds. The eluate 
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collected in the collection tube, containing the RNA samples, were then stored at -
80°C until use.       
 
2.2.5 RNA quantitation and quality assessment 
 
A crucial step post RNA extraction was to assess the concentrations and purity of 
the RNA isolated. The purity and integrity of RNA influences the credibility of the 
results of downstream applications, such as reverse transcription and ultimately PCR 
performance. Nucleic acids (DNA and RNA) achieve optimal absorbance of light 
absorbance (optical density) at a 260nm wavelength. By measuring the optical 
density (OD) at 260nm and hence determining the concentration of RNA by using 
the Beer Lambert Law, there is an assumption that the sample being assessed 
contains purely RNA and does not contain DNA. Therefore, it is a crucial step to 
eliminate DNA in the RNA extraction procedure. By separating the RNA, protein and 
DNA layers in organic extraction, and by ensuring that only the aqueous phase was 
carried over to the following procedures, the probability of DNA contamination was 
significantly reduced.  
Approximately 1.5µL of each isolated RNA sample was added to the pedestal of a 
NanoDrop Spectrophotometer ND-1000. Nanodrop Spectrophotometers provide 
scanning data at various wavelengths that can be analysed to assess the 
concentration and purity of RNA. The ratio of the OD readings recorded at 260nm 
and 280nm (260/280) indicates the purity of the RNA and likely contamination by 
proteins, phenols and aromatic compounds, which absorb optimally at 280nm. Highly 
pure RNA generally has an OD A260/A280 ratio of between 1.8 and 2.1. The ratio of 
the absorbance readings at 260nm over 230nm (260/230) gives an indication of the 
salt contamination in the RNA sample (this being carried over from the high 
concentrations of salts used during the RNA extraction procedure). Contamination 
with salts is generally indicated by an OD A260/A230nm ratio outside the range of 
1.5-2.1. Please refer to Table 2.1 below for concentrations and absorbance ratios 
calculated for the RNA samples extracted. 
  





Table 2.1: RNA concentrations and A260/A280 and A260/A230 ratios for each 
sample of RNA extracted. 
 




         NTC 
SW1116 191.35 2.07 2.09 
DLD1 443.05 2.08 2.17 
         1µM 
SW1116 161.2 2.01 1.78 
DLD1 157.5 2.08 1.84 
          3µM 
SW1116 165.5 2.05 2.01 





SW1116 233.55 2.07 2.01 
DLD1 280.65 2.09 2.14 
300nM 
SW1116 161.45 2.06 1.88 
DLD1 173.2 2.09 1.86 
DMSO 
SW1116 276.3 2.09 2.02 
DLD1 341.95 2.08 2.12 
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2.2.6 miRNA reverse transcription 
 
The RNA samples that had achieved high levels of purity, as determined by the OD 
A260/A280 and A260/A230 ratio’s in Table 2.1 were then subjected to miRNA RT-
PCR. The first step was to convert the extracted total RNA to cDNA. This was 
achieved using the miRNA Reverse Transcription kit from Applied Biosystems. 
Reverse transcription of the total RNA to cDNA was achieved using miRNA-specific 
stem loop primers for miR-143, -145 and -133b, respectively (Applied Biosystems). 
These primers, as discussed in the introduction of this chapter, assist in preparing 
longer cDNA templates that are more amenable to the PCR procedure to follow. 
Table 2.2 contains the reaction mixes that were used for a 15µL volume of RT 
reaction. RNA concentrations were standardised for all samples prior to the Reverse 
Transcription assay.  
 
Table 2.2: Reaction mix volumes for a 15µL Reverse Transcription mix. 
 
RT reaction component 
Volume per 15µL 
reaction volume (µL) 
100mM dNTPs (with dTTP) 0.15 
MultiScribeTM Reverse Transcriptase (50U/µL) 1.00 
10x Reverse Transcription Buffer 1.50 
RNase Inhibitor (20U/µL) 0.19 
Nuclease-free water 4.16 
Total RNA 5 
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RT Master mixes were prepared prior to addition of the RNA samples and RT 
primers. The RT Master mix was centrifuged and separated into 7µL aliquots. 
Volumes of 5 µL of total RNA at a standardized concentration was then added and 
subsequently the addition of 3µL of the miRNA RT primers to each aliquot, adding up 
to the 15µL reaction volumes. These volumes were scaled up according to the cDNA 
end product volumes required for PCR. Reaction mixes were kept on ice for 5 min 
and then transferred to the thermal cycler and run with the parameters shown in 
Table 2.3.  








The above mentioned Reverse Transcription procedure was followed for all cDNA 
samples required for the amplification of miRNAs. The RT reaction for the 
amplification of 18SrRNA did not contain specific reverse transcription primers and 
hence was not done using the miRNA reverse transcription kit. The RT procedure 
was carried out with a conventional TaqMan® Reverse Transcription kit, using 
Random hexamers as the primers to convert total RNA to cDNA. The RT reaction 




Step type Time (min) Temperature (°C) 
HOLD 30 16 
HOLD 30 42 
HOLD 5 85 
HOLD ∞ 4 
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Table 2.4: RT reaction mix for a conventional Reverse Transcription reaction.  
Component 
Volume per 10µL reaction 
volume (µL) 
10x Reverse Transcription Buffer 1 
MgCl2 2.2 
dNTP mix 2 
Random Hexamer2 0.5 
RNase Inhibitor 0.2 
MultiScribeTM Reverse Transcriptase 0.25 
Nuclease-free water and RNA  3.85 
Total 10 
 
2.2.7 miRNA PCR amplification 
 
Real time PCR proceeded using a TaqMan® Universal PCR Master Mix and 
TaqMan® MicroRNA Assays (Applied Biosystems). Refer to Figure 2.5 for the 
reaction volumes per mix. TaqMan® technology utilises the basic concepts of 
polymerase chain reaction (PCR) and fluorescence resonance electron transfer 
(FRET) in combination to yield a superior version of the conventional PCR, more 
accurately amplifying the target being investigated (Kessler et al., 2009). MiRNA 
expression was normalised to the housekeeping non-coding RNA 18s rRNA and 
detected relative to “no treatment controls” in a 7500 Real Time PCR Machine 
(Applied Biosystems). Input cDNA concentrations were standardised prior to 
experimental runs on each cell line. MiRNA-specific TaqMan® MGB probes and 
primers were used to detect expression of the respective miRNAs. Samples were 
run in triplicate to establish a mean Ct value for the amplification of each sample. 
The parameters programmed into the 7500 Real Time PCR machine for each run 
are shown in Figure 2.6.  
                                                          
2
 Random Hexamers were used for the subsequent amplification of the housekeeping gene and endogenous 
control, 18SrRNA. 
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The housekeeping non-coding RNA 18SrRNA was amplified using an assay 
containing the specific primers and probes targeting this gene. This assay was 
commercially available through Applied Biosystems.  
Table 2.5: Reaction volumes for a 20µL PCR mix. 
Component Volume/ 20µL 
reaction (in µL) 
 
TaqMan® miRNA assay 20x or housekeeping gene assay 
 
1 
Product from RT reaction (cDNA) 1.33 
TaqMan® 2X Universal PCR Master Mix, No AmpErase UNG 10 




Table 2.6: Parameters programmed in the Applied Biosystems 7500 Real Time 
PCR Machine for each run. 
Step 




HOLD CYCLE (40 cycles) 
Denature           Anneal/ 
Extend 




95                       60 
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2.2.8 Data analysis 
 
Sample reactions were run in triplicate. The mean Ct values were determined during 
the experimental runs and subsequently the miRNA expression levels from the 
treated samples were first normalised to 18SrRNA and then calculated relative to “no 
treatment controls|, according to the 2-ΔΔCt method described by Livak and 
Schmittgen in 2001 (Appendix C). 
To compare the relationship between the sample means before and after treatment 
with the epigenetic treatments (for the cell viability assays and the RT-PCR 
reactions), a paired two-tailed Student’s t-test was performed with the confidence 
interval set at 95%.  
 
2.3 Results 
2.3.1 The effect of DNA demethylation on cell viability in early and late 
stage colorectal cell lines 
 
To evaluate the susceptibility of SW1116 and DLD1 cell lines to 5-Aza-2’-C 
treatment, the cell lines were subjected to cell viability assays post-treatment with the 
epigenetic drug and compared to the untreated controls.  
Visual changes observed (images not shown) after epigenetic treatment with 5-Aza-
2’-C were evidenced by an altered growth characteristic of DLD1 cells, 
demonstrating a slight decrease in adherent cell growth, recognised by the 
detachment of several cells from the cell culture flask surfaces. The detached cells 
had lost their epithelial morphology and were more granular in appearance.  
In contrast, treating SW1116 cells with 5-Aza-2’-C resulted in a very marginal 
increase in the rate of cell growth. This effect was observed as the cell cultures had 
reached confluency at a slightly faster rate with the treatment of 5-Aza-2’-C. Passage 
cycles were shorter when treated with 5-Aza-2’-C compared to the untreated 
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SW1116 cell cultures.  This ultimately meant that the time for the flask surface to be 
100% confluent was shortened upon treatment with 5-Aza-2’-C.  
These visual changes were supported by the quantitative results obtained from cell 
viability assays completed after treatment with 5-Aza-2’-C. The “no treatment control” 
(NTC) samples for the DLD1 cell line yielded a 97% cell viability while treatment with 
1µM 5-Aza-2’-C decreased cell viability by 6% yielding a value of approximately 91% 
live cells (where t(1) = 4.0288 and p=0.0157; m=97, SD=12.16, n=3) . The number of 
live cells were further decreased to 89% at the increased dose of 3µM 5-Aza-2’-C 












Figure 2.4: DLD1 cell viability post treatment with 5-Aza-2’-C. 
DLD1 cells were treated with differential doses of 5-Aza-2’-C for 
48 hours, with a daily replacement of the drug.  A slight decrease 
in cell viability was observed with 5-Aza-2’-C treatment at 1µM 
and a further decrease noted with 3µM where p=0.0157 and 
p=0.0058, respectively. * Significant (p<0.05); ** Very significant 
(p<0.01) 
 
Cell viability assays conducted on SW1116 cells pre- and post- treatment with 5-
Aza-2’-C correlated with the visual changes that were recognised during cell culture 
with the number of live cells increasing by 1% to a level of approximately 97% 
    *  ** 
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viability when treated with 1µm 5-Aza-2’-C (where t(1) = 0.06718 and p=0.5387; 
m=97, SD=1.41, n=3), compared to 96% viability for the untreated equivalent of the 
cells. However, with an increased concentration (3µm) of the DNA demethylating 
agent, cell viability decreased with a 3% drop in viability to 93%, compared to the 
untreated equivalent (where t(1) = 1.7010 and p=0.1642; m=93, SD=2.16, n=3) 











Figure 2.5: SW1116 cell viability post treatment with 5-Aza-2’-
C. SW1116 cells were treated with differential doses of 5-Aza-2’-C 
for 48 hours with a daily replacement of the drug. There was a 
slight increase in viability at 1µm (p=0.5387, not significant) and a 
slight decrease in viability at 3µm 5-Aza-2’-C (p=0.1642, not 
significant).  
2.3.2 The effect of histone acetylation on cell viability in early and late 
stage colorectal cancer cell lines (SW1116 and DLD1 cells) 
 
The evaluation of the susceptibility of SW1116 and DLD1 cells to the HDACi TSA 
was assessed by performing cell viability assays on the cell lines pre- and post- 
treatment as described in Chapter 2.2.3.  
A microscopy assessment of the DLD1 cells after treatment with 300nM of TSA 
indicated a noticeable increase in non-adherent cells, in suspension in the culture 
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medium. In contrast, DMSO treated cultures were similar to untreated controls, 
where cells remained predominantly attached to the surface of the culture vessel, 
indicating an effect on the cells due to the TSA treatment.  
In corroboration with the above observations, the cell viability assay showed 
untreated cells to be 99% viable, whilst DMSO carrier control cells had a minimally 
decreased viability of some 6% where t(1) = 5.095 and p=0.0047; m=93, SD=1.63, 
n=3. TSA treatment in comparison, resulted in a 15% decrease in DLD1 cell viability 
where t(1)=15.9773 and p=0.0001; m=84, SD=1.41, n=3, denoting a probable effect 











Figure 2.6: DLD1 cell viability post treatment with TSA. DLD1 
cell cultures were treated either with 300nM TSA or an equivalent 
concentration of DMSO (carrier control); or were untreated (NTC) 
for 24 hours. TSA decreased viability of DLD1 cells to 84% 
relative to the “no treatment control” (p=0.0001) whereas DMSO 
treatment only decreased the viability by 6% (p=0.047).  ** Very 
significant (p<0.01), *** Extremely significant (p<0.001) 
  
Similar to the DLD1 cells, the effect of TSA on SW1116 cells resulted in an increase 
in non-adherent cells and an altered cell viability. More specifically, cells in 
suspension were granular in appearance and similar to those seen after the 
treatment of DLD1 cells with 5-aza-2’-C. 
 *** 
  ** 
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Also, a uniform pattern of decreased viability was demonstrated in SW1116 cell 
cultures after treatment with 300nM TSA. The dramatic percentage decrease in 
viable cells compared to the untreated control cells was 18% where t(1)=17.1286 
and p=0.0001; m=80, SD=1.63, n=3. This drop was independent of DMSO as the 
DMSO treated control cells had diminished the percentage of live cells by 6% where 












Figure 2.7: SW1116 cell viability post treatment with TSA. 
SW1116 cell lines were treated with either 300nM TSA or an 
equivalent concentration of DMSO (carrier control) for 24 hours. 
Decreased viability of SW1116 cells was demonstrated upon 
treatment with TSA (p=0.0001), compared with DMSO treatment 
(p=0.0047) and the NTC. ** Very significant (p<0.01), ***Extremely 
significant (p<0.001). 
 
2.3.3 The effect of DNA de-methylation on miRNA expression in early stage 
colorectal adenocarcinoma 
 
To assess the contribution of DNA de-methylation on the expression of the three 
miRNAs in question in early stage CRC, SW1116 cells were treated with both a low 
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cDNA by reverse transcription, the samples were subjected to real time PCR to 
detect relative expression of the miRNAs to the untreated controls. The Ct values 
were first normalised to the endogenous control, 18s rRNA, after which fold changes 
in expression were calculated according to the 2-ΔΔCt method (Livak & Schmittgen, 
2001). The sample ΔCt mean values for treatment and untreated samples were 
compared for statistical significance using a paired two-tailed Student’s t-test, with 
the confidence interval set at 95%.  














Figure 2.8: Relative expression of miR-133b in SW1116 cells 
after treatment with 5-Aza-2’-C. Low and high dose 5-Aza-2’-C 
treatment yield increased miR-133b expression by 1.6 (p=0.0282) 
and 1 fold (p=0.0047) respectively. *Significant (p<0.05), ** Very 
Significant (p<0.01).  
 
The effect of the two dosages of 5-Aza-2’-C on the expression of miR-133b is 
illustrated in Figure 2.8. MiR-133b expression increased by over 1.6 fold after 
treatment with 1µM 5-Aza-2’-C, compared to the no treatment control (NTC), where 
   ** 
    * 
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t(1) = 22.5577 and p=0.0282 (m=5.865, SD=0.26, n=3). A similar trend is shown for 
the treatment of SW1116 cells at the higher dose of 3µm 5-Aza-2’-C; miR-133b was 
also significantly up-regulated, where t(1) = 5.69382) and p=0.0047 (m=3.21, SD = 
0.481, n=3), albeit some 0.5 fold less than the increase exhibited with the low dose 
treatment. From this, it would seem that there may be a dose dependent relationship 
of the 5-Aza-2’-C treatment on miR133b expression.  













Figure 2.9: Relative expression of miR-143 in SW1116 cells 
after treatment with 5-Aza-2’-C.   Low dose (1µm) 5-Aza-2’-C 
yielded increased miR-143 expression by almost 2 fold 
(p=0.0157), while there was a marginal increase of 0.01 fold 
(p=0.503, not significant) after high dose (3µm) 5-Aza-2’-C 
treatment. * Significant (p<0.05). 
 
To evaluate the effect of DNA de-methylation on miR-143 expression in early stage 
CRC cells, expression levels of miR-143 relative to the untreated controls were 
compared, after treating SW1116 cells with a low and a high dose  of 5-Aza-2’-C, 
respectively (Figure 2.9).  
 * 
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The expression of miR-143 was effectively induced by the treatment of 1µm 5-Aza-
2’-C by almost 2 fold (where t(1)=40.5576 and p=0.0157 (m=6.50950, 
SD=0.16,n=3)). However at a higher concentration (3µm) this induced expression 
was lost, demonstrating a marginal but insignificant up-regulation of 0.018 fold, 
compared to the untreated control (where t(1)=0.735 and p=0.503 (m=-0.264, 
SD=1.003, n=3)). The expression of miR-143 was more responsive to the lower dose 
of 5-Aza-2’-C than the higher 3µm dose, demonstrating a dose-specific response.  










Figure 2.10: Relative expression of miR-145 in SW1116 cells 
after treatment with 5-Aza-2’-C. Low dose (1µm) and high dose 
(3µm) 5-Aza-2’-C yield increased miR-145 expression by 2.3 fold 
(p=0.0177) and 1.8 fold (p=<0.00001) respectively. * Significant 
(p<0.05), *** Extremely significant (p<0.001).  
 
SW1116 cells were treated with a lower (1µm) and higher dose (3µm) of 5-Aza-2’-C 
and its effect on miR-145 expression was evaluated (Figure 2.10). At the lower dose, 
miR-145 was significantly up-regulated by 2.4 fold, relative to the control cells; the 
mean decrease in the Ct value was significant, where t(1)= 36.0390 and p=0.0177 
(m=7.388, SD = 0.205, n=3). Similarly with a dose of 3µm 5-Aza-2’-C, miR-145 was 
effectively up-regulated by 1.8 fold compared to the untreated control samples; 
where the mean decrease in Ct was highly significant, with t(1) = 33.2513 and 
*** 
  * 
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p<0.00001 (m=6.24, SD=0.771, n=3). Additionally, miR-145 expression seemed to 
be more susceptible to the lower dose of 5-Aza-2’-C, with an almost 0.5 fold increase 
in expression when compared to the lower dose.   
2.3.4 The effect of DNA methylation on miRNA expression in late stage 
colorectal adenocarcinoma 
 
To determine the contribution of DNA de-methylation on the expression of the three 
miRNAs in question in late stage CRC, DLD1 cells were treated with low and high 
dose 5-Aza-2’-C.  Isolated RNA was reverse transcribed and miRNA expression 
levels were assessed as described previously, relative to the endogenous control 
18s rRNA.  
2.3.4.1 The effect of 5-Aza-2’-C treatment on the expression of miR-133b 
 
Figure 2.11: Relative expression of miR-133b in DLD1 cells 
after treatment with 5-Aza-2’-C. Low dose (1µm) yielding an 
increased expression of miR-133b by 2.3 fold (p=0.1179, not 
significant) while high dose (3µm) 5-Aza-2’-C exhibits down-
regulation of miR-133b by 2,8 fold (p=0.0870, not significant). 
Relative expression is shown as log(2
-ΔΔCt ,base 2).  
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To quantify the effect of DNA de-methylation on miR-133b expression in late stage 
colorectal adenocarcinoma, DLD1 cells were treated with low (1µm) and high (3µm) 
dose 5-Aza-2’-C for 48 hours each and qRT-PCR was subsequently conducted to 
detect the expression of miR-133b pre- and post- treatment. According to Figure 
2.11, relative expression of miR-133b compared to untreated controls yielded a trend 
of upregulation by 2.3 fold when treated with 1µm 5-Aza-2’-C where t(1)=5.3399 and 
p=0.1179 (m=6.747, SD=1.264, n=3). Alternatively, a trend of down-regulation of 
miR-133b by 2.8 fold, where t(1)=7.2755 and p=0.0870 (m=-9.811, SD=1.349, n=3), 
is evident when DLD1 cells are treated with the higher dose of 5 aza-2’-C. This 
implies a dose sensitive response of miR-133b to the DNA de-methylating agent. In 
comparison to Figure 2.5, where early stage colorectal carcinoma cells (SW1116) 
were treated with 5-Aza-2’-C and the expression of miR-133b evaluated, it would 
seem that miR-133b expression in SW1116 cells was more susceptible to DNA 5-
Aza-2’-C at the higher dose of 3µm than in DLD1 cells. In contrast however, the 
susceptibility to the 1µm dose was retained in both cell lines, with highest 
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Figure 2.12: Relative expression of miR-143 in DLD1 cells 
after treatment with 5-Aza-2’-C. Low dose (1µm) yielding an 
increased expression of miR-143 by 3.7 fold (p=0.005), while high 
dose (3µm) 5-Aza-2’-C exhibits down-regulation of miR-143 by 1 
fold (p=0.0238). Relative expression is shown as log(2
-ΔΔCt , base 
2). * Significant, (p<0.05), ** Very Significant (p<0.01). 
 
MiR-143 expression was assessed in DLD1 cells after treatment with 1µm and 3µm 
doses of 5-Aza-2’-C for 48 hours (Figure 2.12). Quantification of miR-143 by qRT-
PCR revealed that when the DLD1 cells were treated with 1µm 5-Aza-2’-C, the mean 
decrease in Ct was found to be significant, where t(1)=126.246 and p=0.005 
(m=11.804, SD=0.093, n=3), implying that miR-143 was significantly up-regulated by 
3.7 fold. In contrast, a mean increase in Ct was found to be significant where 
t(1)=26.7616 and p=0.0238 (m=3.76, SD=0.14, n=3), indicating that treatment with 
the higher dose of 3µm resulted in down-regulation of miR-143. When comparing 
these results to the quantitative results of the effect of 5-Aza-2’-C on miR-143 in the 
early stage CRC cell line SW1116 (Figure 2.9), it is immediately recognised that in 
both cell lines miR-143 is more susceptible to 1µm 5-Aza-2’-C than the higher dose 
of 3µm.  
 ** 
  * 
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Figure 2.13: Relative expression of miR-145 in DLD1 cells 
after treatment with 5-Aza-2’-C. Low dose (1µm) yielded an 
increased expression of miR-145 by 4.3 fold (p=0.001) while high 
dose (3µm) 5-Aza-2’-C exhibited marginal increase of miR-143 by 
0.1 fold (p=0.00001). Relative expression is shown as log (2
-ΔΔCt, 
base 2). *** Extremely significant (p<0.001) 
 
Assessing the relative expression of miR-145 to the untreated controls in DLD1 cells 
after treatment with 1µm 5-Aza-2’-C revealed a mean decrease in Ct that was found 
to be significant where t(1)=610.3696 and p=0.001 (m=14.0385, SD-0.023, n=3), 
substantiating that miR-145 was effectively up-regulated by 4.3 fold relative to the 
untreated controls. On the other hand, when DLD1 cells were treated with 3µm 5-
Aza-2’-C, only a slight increase in the expression of the miRNA was apparent. This 
result was found to be significant, where t(1)=28.070365 and p=0.00001 (m=0.3275, 
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2.3.5 The effect of histone de-acetylation on miRNA expression in early 
stage colorectal cancer 
 
To assess the contribution of histone de-acetylation on the expression of the three 
miRNAs in question in early stage CRC, SW1116 cells were treated with TSA 
(300nM) and additionally with the carrier control DMSO.  After isolating RNA and 
subsequent conversion to cDNA by reverse transcription, the samples were 
subjected to real time PCR to detect relative expression of the miRNAs to the 
untreated controls. After normalizing, the Ct values to the endogenous control, 18s 
rRNA, fold changes in expression were calculated according to the method of Livak 
& Schmittgen, 2001. The sample ΔCt mean values for treatment and untreated 
samples were compared for statistical significance using a paired two-tailed 
Student’s t-test, with the confidence interval set at 95%. 
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Figure 2.14: Relative expression of miR-133b in SW1116 cells 
after treatment with TSA. Treatment with the HDACi TSA 
increased the expression of miR-133b by 3.3 fold (p=0.0353) in 
comparison to 2.5 fold by DMSO (p=0.0101). Relative expression 
is shown as log(2
-ΔΔCt , base 2). * Significant (p<0.05) 
 
The impact of histone acetylation on the expression dynamics of miR-133b in early 
stage colorectal adenocarcinoma was assessed by treating SW1116 cells with 
300nM TSA and thereafter quantitatively determining the expression of miR-133b by 
qRT-PCR (Figure 2.14). The histone de-acetylase inhibitor had significantly 
increased the expression of miR-133b by 3.3 fold, where t(1)=18.0408 and p=0.0353 
(m=10.175, SD=0.564, n=3). To eliminate the effects of the carrier control, DMSO, 
on the result received by the treatment of TSA, a DMSO control was assessed for 
expression of miR-133b. As shown in Figure 2.11, DMSO had induced a significant 
increase in miR-133b expression by 2.5 fold, where t(1)=62.7744 and p=0.0101 
(m=8.349, SD=0.133, n=3). Although DMSO had also induced expression of the 
miR-133b, this was 0.8 fold less than the expression for miR-133b after treatment 
with 300nM TSA. The net result of TSA treatment remains an up-regulation of 
miR133-b expression. 
  * 
    * 
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Figure 2.15: Relative expression of miR-143 in SW1116 cells 
after treatment with TSA. Treatment with the HDACi TSA 
increased the expression of miR-143 by 3.7 fold (p=0.0759, not 
significant) in comparison to 1.8 fold by DMSO treatment 
(p=0.0028). Relative expression is shown as log(2
-ΔΔCt , base 2). 
**Very significant (p<0.01) 
 
To assess the impact of histone de-acetylation on miR-143 expression in early stage 
colorectal adenocarcinoma, SW1116 cells were treated with 300nM TSA for 24 
hours, after which miR-143 was quantified by qRT-PCR (Figure 2.15). It was 
determined that relative to the no treatment controls, when the cells were treated 
with 300nM TSA, miR-143 had increased in expression by 3,7 fold (where 
t(1)=8.3488 and p = 0.0759 (m=12.0765, SD=1.446, n=3). Despite not being a 
significant correlation, DMSO alone only increased the expression of miR-143 by 1.8 
fold, almost 1.9 fold less than that of 300nM TSA. The quantification of miR-143 post 
treatment with DMSO was found to be significant where t(1)=227.9091 and p=0.0028 
(m=6.2675, SD=0.027, n=3). The results indicate that TSA treatment of SW1116 
cells yielded a net upregulation of miR-143 by 1.9 fold. 
 
 
   ** 
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Figure 2.16: Relative expression of miR-145 in SW1116 cells 
after treatment with TSA. Treatment with the HDACi TSA 
increased the expression of miR-145 by 3.8 fold (p=0.0508, not 
significant) in comparison to 1.7 fold with DMSO (p=0.0332). 
Relative expression is shown as log(2
-ΔΔCt ,base 2). *Significant 
(p<0.05). 
 
When SW1116 cells were treated with TSA and its effect on the expression of miR-
145 was quantified, a similar expression pattern to miR-143 (Figure 2.15) was 
realised. Treatment with 300nM TSA resulted in a mean decrease in Ct, where 
t(1)=12.5174 and p=0.0508 (m=11.178, SD=0.893, n=3), providing evidence that 
treatment with TSA demonstrates a trend of up-regulation of miR-145 by 3.8 fold, 
relative to the no treatment control. DMSO treatment alone had induced the 
expression of miR-145 by 1.7 fold, where t(1)=19.1536 and p=0.0332 (m=5.7365, 
SD=0.3, n=3), yielding a significant result that is approximately 2 fold lower than the 
TSA treatment inclusive of DMSO. This result indicates a net up-regulation of miR-
145 after treatment of 300nM TSA by about 2 fold from the no treatment controls. 
(Figure 2.16) 
 
    * 
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2.3.6 The effect of histone acetylation on miRNA expression in late stage 
colorectal cancer 
 
The effect of histone acetylation in late stage CRC was assessed by treating DLD1 
cells with 300nM TSA and the DMSO carrier control after which the three miRNAs in 
question, miR-143, 145 and 133b, were quantified by miRNA qPCR, relative to the 
no treatment controls.  Mean Ct values for triplicate samples were analysed for fold 
change and subjected to a paired two-tailed Students t-test to evaluate the statistical 
significance with the confidence interval set at 95%.    












Figure 2.17: Relative expression of miR-133b in DLD1 cells 
after treatment with TSA. Treatment with the HDACi TSA 
decreased the expression of miR-133b by 0.5 fold (p=0.32, not 
significant). DMSO treatment increased miR-133b expression by 
0.2 fold (p=0.1171, not significant). Relative expression is shown 
as log(2
-ΔΔCt , base 2).  
 
During late stage colorectal adenocarcinoma by virtue of DLD1 cells, miR-133b 
expression was assessed after treatment with 300nM TSA and the carrier control 
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DMSO (Figure 2.17). An antagonistic relationship between the treatment with TSA 
and miR-133b is demonstrated whereby treatment with TSA resulted in a mean 
increase in Ct, exhibiting a decrease in miR-133b expression by 0.5 fold from the no 
treatment control [t(1) = 1.8189, p=0.32 (m=-1.6725, SD=0.919, n=3)]. This effect 
seems to be independent of the DMSO vehicle, as DMSO alone had demonstrated a 
mean decrease in Ct, where t= 5.3758, p=0.1171 (m=0.887, SD=0.165, n=3), 
showing increased expression of miR-133b by 0.26 fold.  









Figure 2.18: Relative expression of miR-143 in DLD1 cells 
after treatment with TSA. Treatment with the HDACi TSA 
decreased the expression of miR-143 by 0.4 (p=0.3277, not 
significant) fold while DMSO treatment decreased miR-143 
expression by 0.08 fold (p=0.007515). Relative expression is 
shown as log(2
-ΔΔCt ,base 2). ** Very Significant (p<0.01). 
 
MiR-143 expression in late stage colorectal adenocarcinoma after treatment with 
300nM TSA revealed a result reminiscent of the effect of the epigenetic drug 
treatment on miR-133b (see Figure 2.17). As depicted in Figure 2.18, miR-143 had 
decreased by 0.4 fold relative to the no treatment. This mean increase in Ct was 
found to be non-significant where t(1)=1.7683 and p=0.3277 (m=-1.038, SD=0.587, 
n=3). This result was also found to be independent of the DMSO carrier molecule. 
  ** 
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Treatment with DMSO alone had significantly decreased miR-143 expression by 
0.08 fold, where t(1)=6.463078 and p=0.007515 (m=-0.9665, SD=0.252, n=3). Thus 
here, the observed decrease in miR-143 was specifically in response to the 
treatment with TSA.  
2.3.6.3 The effect of TSA on the expression of miR-145 
 
Figure 2.19: Relative expression of miR-145 in DLD1 cells 
after treatment with TSA. Treatment with the HDACi TSA 
decreased the expression of miR-145 by 0.07 (p=0.6591, not 
significant) fold whereas DMSO treatment alone decreased miR-
1245 expression by almost 0.2 fold (p=0.3383, not significant). 
Relative expression is shown as log(2
-ΔΔCt ,base 2).  
 
MiR-145 expression in late stage colorectal adenocarcinoma was also found to be 
marginally affected by the treatment with 300nM TSA. The mean Ct was slightly 
increased compared to the no treatment control, where t(1)=0.5934 and p=0.6591 
(m=-0.1255, SD=0.211, n=3). Therefore miR-145 expression decreased slightly by 
0.07 fold, relative to the no treatment control. It is however questionable whether this 
result was caused by TSA, as the DMSO carrier control exhibited a mean increase in 
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Ct, where t(1)=1.7012 and p=0.3383 (m= -0.427, SD=0.251, n=3). An almost 0.2 fold 
decrease in expression was noted with the treatment of DMSO alone (Figure 2.19). 
2.4 Discussion 
  
The consistent pattern of downregulation of miRNAs -143, -145 and -133b in CRC 
and several other cancers proposes these miRNAs as potential targets of epigenetic 
regulation.  To evaluate the effect of epigenetic regulation by virtue of DNA 
methylation and histone acetylation on the expression of these CRC associated 
miRNAs, the colorectal adenocarcinoma cell lines SW1116 and DLD1, representing 
an early and late stage of CRC, respectively, were treated individually with one of 
two categories of epigenetic drugs, either a DNA demethylating agent, 5-Aza-2’-C or 
a HDACi, TSA.   
2.4.1 Appropriate use of cell lines 
 
The use of established cancer cell cultures remains the most accessible and 
reproducible in vitro method for cancer research purposes (Kao et al., 2009). For this 
study the CRC cell lines SW1116 and DLD1 were selected as they represent distinct 
yet progressive stages of CRC tumours. SW1116 cells are a Dukes’ stage A, Grade 
III colorectal adenocarcinoma obtained from a 73 year old Caucasian male. The 
DLD1 cells are a Dukes’ stage C colorectal carcinoma from a Caucasian adult male. 
The use of these two disparate stages allows for the evaluation of the response of 
early and late stage tumours to the aforementioned pharmacological treatments.    
The classification of CRC was first devised by the pathologist Cuthbert Dukes, a 
British pathologist (Dukes, 1932). The classification system, evidently termed Dukes’ 
staging, classifies colorectal tumours into four stages, from A-D. Stage A (SW1116) 
refers to tumours that are confined to the mucosa. Stage B is represented by 
tumours invading the bowel wall and penetrating the muscle layer, however without 
any involvement of lymph nodes. Stage C (DLD1) CRC tumours present with lymph 
node involvement and Stage D is depicted by tumours with widespread metastasis. 
The Dukes’ staging classification is however outdated in clinical practice and has 
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been replaced by the more detailed TNM staging. Refer to  Figure 2.20 below which 









Figure 2.20: TNM staging vs Dukes Staging. TNM staging has 
been formulated by the American Joint Commission on Cancer. The 
more detailed TNM staging has replaced the outdated Dukes 
staging. Key: Tis = carcinoma in situ, T0= no primary tumour 
evidence, T1 = tumour has invaded the submucosa, T2 = tumour has 
penetrated the muscularis propria, T3 = Tumour has invaded 
subserosa and into peritonalised pericolic or perirectal tissues, T4 = 
the tumour invades other organs or structures and/or piercing the 
visceral peritoneum. N0 = no evidence of metastasis to any lymph 
nodes, N1 – one to three lymph node involvement, N2 – metastasis 
to four or more lymph nodes. M0 = no evidence of distant 




Cancer cell lines have also been reported to be suitable in vitro models to study 
epigenetic features of cancer (Ferreira et al., 2013). To allow for an accurate 
analysis of the assays conducted with these cell lines, it is important to understand 
the molecular characteristics of each cell line. The established characteristics for the 
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Table 2.7: Genetic and Epigenetic features of SW1116 and DLD1 cell lines.3 
SW1116 cell  line DLD1 cell line 
Dukes’ Stage A/Stage I Dukes’ Stage C/Stage III 
MSS (Microsatellite Stable)/CIN + MSI (Microsatellite Instable)/CIN - 
*CIMP Panel 1 + CIMP Panel 1 + 
**CIMP Panel 2 - CIMP Panel 2 + 
KRAS mutant [G12A] KRAS mutant [G13D] 
wt BRAF wt BRAF 
wt PIK3CA PIK3CA mutant [E45K; D549N] 
wt PTEN wt PTEN 
TP53  mutant [A159D] TP53 mutant [S241F] 
 
 (Adapted from Ahmed et al., 2013) 
 
2.4.2 The effect of DNA demethylation on cell viability in early and late 
stage colorectal cancer 
 
As a first approach here, cell viability of each cell line was assessed following 
treatment with 5-Aza-2’-C, since it has previously been shown to suppress tumour 
cell line growth (Bender et al., 1998). This served to indicate the effects of DNA 
demethylation on the in vitro growth of the early and late stage CRC cells. 
Foreseeably, DLD1 cells displayed decreased cell viability in a dose dependent 
manner upon treatment with 5 aza-2’-C. However, in the SW1116 cells although 
there was a marginal increase in the percentage cell viability at the lower dose of 
1µm 5-Aza-2’-C, there was nevertheless a slight decrease in cell viability at the 
higher dose (3µm) of 5-Aza-2’-C.  
The non-susceptibility of SW1116 cells to 5-Aza-2’-C is inconsistent with published 
literature reporting on the antitumour effects of 5-Aza-2’-C. Although the 
mechanisms whereby 5-Aza-2’-C accomplishes its anti-tumour effects are not fully 
                                                          
3
 *CIMP Panel 1+ indicates mutations in CDKN (p16), MINT 1, MINT 2, MINT 31 and MLH1                                                 
 **CIMP Panel 2+ indicates mutations in CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 
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elucidated. The first postulated mechanism of cytotoxicity relates to the reactivation 
of aberrantly silenced genes that ultimately function to control and regulate cell 
proliferation and apoptosis. The second idea relates to the treatment with 5-Aza-2’-C 
being recognised as DNA damage due to the covalent DNMT-DNA adducts that 
form, following which the DNA damage response pathways would then be 
responsible for the cytotoxic effects (Palii et al., 2008). 
A key difference in the characteristics of the two cell lines is that DLD1 cells are 
microsatellite instable (MSI), whereas SW1116 cells are microsatellite stable (MSS) 
(see Table 2.7; Ahmed et al., 2013). SW1116 cells being microsatellite stable (MSS) 
indicates the presence of unstable chromosome translocations with gains or losses 
of whole chromosomes as described in Chapter 1.2 (Lengauer et al., 1998). 
Generally this transient instability of the chromosomes occurs early in the 
development of cancer which is likely the case as SW1116 represents Dukes’ Stage 
A or Stage I of CRC.   
As already mentioned in Chapter 1.2, the MSI phenotype is characterised by 
deficiencies in the DNA mismatch repair (MMR) pathway specifically as a result of 
mutation or hyper-methylation of the MLH1, MSH2 or MSH6 genes (Peltomaki et al., 
2001). The susceptibility of DLD1 cells to 5-Aza-2’-C as shown here is potentially a 
result of reactivated MLH1, which is aberrantly silenced by hyper-methylation in MSI 
CRC.  It has previously been reported that 5-Aza-2’-C treatment was able to re-
express MLH1 in the colon cancer xenograft SW48 (MSI) in which MLH1 was 
silenced through promoter hyper-methylation (Plumb et al., 2000). Moreover, this re-
expression of MLH1 sensitised the xenografts to several chemotherapeutic agents.  
MLH1 is known to induce apoptosis and cell cycle arrest in response to DNA 
damage, by signalling for p53 mediated apoptosis. MLH1 p53-independent apoptosis 
mediated by c-Abl/p73α/GADD45α has also been reported (Fukuhara et al., 2014). 
This p53-independent apoptotic pathway may be relevant to DLD1 cells should 
MLH1 be reactivated after treatment with 5-Aza-2’-C as DLD1 cells are carriers of a 
p53 mutation, a common feature of MSI CRC (Ahmed et al., 2013). Confirmation of 
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apoptosis in response to 5-Aza-2’-C treatment however has not been determined in 
this study and would require further analysis.     
In addition to MLH1, promoter hyper-methylation of p16 has also been demonstrated 
in MSI CRC which also associates with advanced Dukes’ staging, such as DLD1 
cells (Shannon et al., 2001). P16 is a cyclin-dependent kinase inhibitor and functions 
as a tumour suppressor by binding and inactivating cyclin D-cyclin-dependent kinase 
4 thereby inactivating the Retinoblastoma protein which blocks transcription of cell 
cycle genes and which ultimately triggers cell senescence (Ligget et al., 1998).  
In summary, the MSI CRC cell lines such as DLD1 are more susceptible to treatment 
with 5-Aza-2’-C potentially through the reactivation of silenced tumour suppressor 
genes. The differential susceptibility demonstrated by SW1116 cells concurs with the 
evidence that MSI tumours are likely to show higher levels of methylation than MSS 
tumours; and also that increased methylation is associated with a more advanced 
tumour stage (Hawkins et al., 2002).   
2.4.3 The effect of histone acetylation on cell viability in early and late 
stage colorectal cancer 
 
In keeping with the ability of epigenetic modulators to inhibit proliferation of cancer 
cells, cell viability assays post treatment with TSA was performed for both cell lines. 
TSA treatment at concentrations of 300nM for 24 hours potently decreased the 
viability of both early (SW1116) and late (DLD1) stage CRC cell lines. DMSO was 
used as a TSA drug vehicle to enable cellular access of the HDACi. DMSO however 
has also been found to alter gene expression, cell morphology and cell viability in a 
dose dependent manner (Pal et al., 2012). To determine whether the cytotoxic 
effects were an independent result of TSA treatment, cell viability after treatment 
solely with an equivalent DMSO concentration was also assessed. The resulting 
decrease in cell viability in response to DMSO treatment was much lower in both cell 
lines in comparison to TSA, indicating here that TSA is responsible for cell death in 
early and late stage CRC cell lines.  
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These results are not unexpected as HDACi’s have long been known and 
appreciated to induce cell cycle arrest and cell death in cancer cells (Dokmanovic et 
al., 2007).  TSA in particular causes cell cycle arrest in the G1 and G2 cell cycle 
phases (Yoshida et al., 1988). In addition, TSA treatment has been shown to 
upregulate proteins that are pro-apoptotic and downregulate proteins that repress 
apoptosis (Meng et al., 2012; Liu et al., 2013; Duan et al., 2005; Kim et al., 2006; 
Moore et al., 2004). Cell death induced by HDACi has been characterised by several 
mechanisms as depicted in Figure 2.21 below. Apoptosis was induced via the 
intrinsic (Duan et al., 2005) and extrinsic (Kim et al., 2006) pathways upon inhibition 
of HDAC. In addition, HDACi treatment can also induce autophagic cell death; 
autophagy is a catabolic pathway in which proteins and organelles in the cytoplasm 
are sequestered into vacuoles and transported to the lysosome for degradation and 
recycling (Rikiishi, 2011). Another mechanism of HDACi induced cell death is 
through mitotic catastrophe caused by alterations in G2M checkpoint gatekeeper 
proteins, DNA repair mechanisms and alterations in proteins involved in mitotic 
spindle formation and chromosome segregation during mitosis (Cornago et al., 
2014). Treatment with HDACi is also associated with senescence, an irreversible 
halt on cell division (Vargas et al., 2014), and cell death facilitated by an increase in 
reactive oxygen species (ROS) (Ungerstedt et al., 2004). 
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Figure 2.21: HDACi induced cell death. HDACi mediates cell 
death through various pathways, including the intrinsic and 
extrinsic pathway, mitotic catastrophe, autophagy, senescence 
and ROS facilitated cell death (Adapted from Xu, et al., 2007).   
 
In CRC TSA has demonstrated cytotoxicity in various ways. Chen et al. in 2004 
elucidated the growth inhibitory role that TSA plays in SW1116 cells. TSA had 
induced G1 phase arrest in SW1116 cells and had demonstrated a significant 
increase in p21(WAF1) expression. In addition, it was shown that Histones 3 and 4 in 
the chromatin associated with the p21 (WAF1) gene was acetylated, indicating a 
direct effect of TSA and histone acetylation on the expression of p21(WAF1). P21 
(WAF1) functions as a CDK inhibitor and therefore limits the progression of the cell 
cycle. An intimate relationship between p21 (WAF1) and p53 has been documented 
thoroughly in which p53 mediates growth arrest, following DNA damage, by inducing 
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p21 (WAF1) which in turn alters DNA replication by forming complexes with PCNA 
(proliferating cell nuclear antigen), an auxiliary factor to DNA Polymerase δ and ε, a 
preceding event to altering DNA replication (Xiong et al., 1992). SW1116 and DLD1 
cells are however p53 deficient and therefore the induction of p21 (WAF1) in 
SW1116 cells would indicate alternative mechanisms that are independent of the 
relationship with p53. P53 independent induction of p21 has been reported despite 
the mechanisms not being fully elucidated (Macleod et al., 1995). One potential path 
of p21 (WAF1) activation in a p53 deficient environment is through STAT1 (Chin et 
al., 1996). Another described mechanism of p21 (WAF1) induction is through histone 
deacetylases. HDAC3 is overexpressed in colon cancer and has been found to 
regulate the expression of p21 (WAF1) in an inverse proportional manner (Wilson et 
al., 2006). Furthermore, HDAC inhibitors have been reported to directly induce p21 
(WAF1) by hyperacetylation of histones in the chromatin region around the p21 
(WAF1) promoter (Richon et al., 2000). These two mechanisms are potentially the 
cause of the potent reduction in cell viability.  
In the present study, when comparing the effect of DNA demethylation versus that of 
histone deacetylase inhibition on the cell viability in both cell lines, it is evident that 
TSA decreases the cell viability in both cell types more so than DNA demethylation, 
this possibly being due to various cell death pathways being initiated (see Fig. 2.21 
above).  
 
2.4.4 The stage specific effect of DNA demethylation on the expression of 
miRNAs 
 
All three miRNAs in question had demonstrated clear upregulation in both cell lines 
upon treatment with 5-Aza-2’-C at the lower dosage of 1µm. The susceptibility of 
miRNAs in both cell lines to 5-Aza-2’-C was however much less at a higher dosage 
of 3µm with the DLD1 cell line showing the least susceptibility of the miRNAs to the 
higher dose, where downregulation patterns of miR-133b and miR-143 were 
obtained. A negligible change was also achieved for miR-143 in SW1116 cells in 
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response to the higher dose. These results demonstrate a dose sensitive response 
to the DNA demethylating agent 5-Aza-2’-C, wherein miRNAs are upregulated at low 
doses of 5-Aza-2’-C.  
The initial use of 5-Aza-2’-C as a therapeutic anti-tumour agent was assessed at the 
maximum tolerated dose in several cancers and the result was of high toxicity and 
low efficacy, with exceptions in Myelodysplastic Syndrome (MDS) and Acute Myeloid 
Leukaemia eventually leading to its approval by the FDA for treatment of MDS 
(Kantarjian et al., 2006). Increased efficiency of the “pro-drug” was however 
recognised only when low transient doses were used (Wijermans et al., 1997; 
Wijermans et al., 2000; Tsai et al., 2012). In the present study, the susceptibility of 
the miRNAs to the lower dose concurs with this finding. It is thought that the low 
dosage levels induce more hypomethylation, while the higher doses induce more 
cytotoxicity which confounds the effects of DNA demethylation. This was also 
supported by the evidence that  5-Aza-2’-C treatment produces a U-shaped 
hypomethylation response curve, which indicates that DNA hypomethylation levels 
increase with increasing doses of 5-Aza-2’-C until a point at which it reaches a 
trough of maximum hypomethylation, after which with increasing doses the 
hypomethylation effect decreases (Qin et al., 2009).   If it is verifiable that the lower 
doses of the DNA demethylating agent are more able to re-express silenced tumour 
suppressor genes in CRC, then the present result achieved here is indicative that at 
1µM the miRNAs are transcriptionally activated by DNA demethylation.  This could 
be directly through removal of methyl groups from the promoter regions of each 
miRNA, or indirectly through the activation of transcription factors that are 
themselves reactivated through DNA demethylation and are involved in miRNA-
transcription factor feedback regulation loops.  To confirm if the miRNA activation is 
through the direct effect of DNA demethylation of CpG islands in the promoter 
regions, sequencing of bisulfite modified DNA coupled with methylation specific PCR 
will need to be completed pre- and post- treatment with 5-Aza-2’-C.  
A previous study has determined that miR-145 is repressed by DNA methylation in 
which the promoter region was found to be hypermethylated in prostate cancer cells 
and various other cell lines (Suh et al., 2011). In the study, it was also determined 
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that downregulation of miR-145 in tumour cell lines was highly correlated with cell 
lines containing p53 mutations. Furthermore, miR-145 has also recently been found 
to be epigenetically silenced by promoter hypermethylation in oesophageal 
carcinoma (Harada et al., 2015).  Although Suh et al. (2011) had also reported miR-
145 promoter methylation in several colon cancer cell lines, interestingly the 
SW1116 cell line was found to be negative for miR-145 methylation. In the same 
study the HT29 and SW620 colorectal cell lines were also tested and found to be 
positive for miR-145 methylation. HT29 and SW620 cell lines are both Dukes’ Stage 
C and have p53 mutations, resembling the molecular characteristics of DLD1 cells. It 
is possible that DLD1 cells are positive for miR-145 methylation, which could explain 
the increased susceptibility of miR-145 in DLD1 cells, when compared to SW1116 
cells in response to 5-Aza-2’-C.  
MiR-145 and miR-143 are polycistronic miRNAs, indicating that they are transcribed 
from the same promoter (Iio et al., 2010). This would signify that the promoter 
methylation status should impact both miRNAs. Silencing of miR-143 via promoter 
methylation has only been reported thus far in MLL-AF4 acute lymphocytic 
leukaemia (Dou et al., 2012). In the present study, although both miRNAs were 
induced by 1µM 5-Aza-2’-C, these were at varying levels. These differential levels of 
induction of both miRNAs by 5-Aza-2’-C could be explained by post-transcriptional 
regulation of the miRNA maturation process. P53 has been demonstrated to be 
involved in inducing the expression of the miR-143/145 cluster in a transcription-
independent manner; however as SW1116 and DLD1 cells are p53 deficient, it could 
be assumed that a different transcription factor may be involved in the post 
transcriptional maturation of the miRNAs (Suzuki et al., 2009).  
MiR-133b expression, also induced by 5-Aza-2’-C in this study in both cell lines at 
the lower dose and only in SW1116 cells at the higher dose, correlates with the 
recent finding by LV et al. (2015) who reported that miR-133b promoter 
hypermethylation is causal for its low levels in CRC. No further evidence has been 
determined regarding epigenetic regulation of miR-133b.  
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When comparing early versus late stage CRC expression of miRNAs after 5-Aza-2’-
C treatment, all miRNAs are more responsive to the lower dose of 5-Aza-2’-C in 
DLD1 cells compared to SW1116 cells. For miR-145 this could be explained by the 
discrepancy in the promoter hypermethylation at different stages as indicated by the 
lack of promoter hypermethylation in SW1116 cells and the presence of miR-145 
methylation in several Dukes’ stage C/p53 mutant CRC cell lines (Suh et al., 2011).   
Another potential reason for a discrepancy in susceptibility is that 5-Aza-2’-C is an S-
phase acting drug which means that it induces its effect in cells that are actively 
replicating. SW1116 is a slow growing cell line with a higher doubling time than 
DLD1 cells. Thus it may be assumed that the SW1116 cells have a proportionately 
lower ratio of cells in the S-phase than DLD1 cells at a given time point. Considering 
that the treatment times were the same for both cell lines, a discrepancy in DNA 
demethylation levels could explain the lower levels of upregulation of miRNAs in the 
SW1116 cell line. This would need to be confirmed by measuring the methylation 
levels of the cell line pre- and post- treatment with 5-Aza-2’-C. 
In addition to the above, miRNA signatures have been insinuated to discriminate 
between MSI versus MSS colorectal tumours (Lanza et al., 2007). Although this 
initial study did not report on differential patterns between miR-145, -143 and -133b 
in MSI as opposed to MSS CRC, a later study in 2011 by Balaguer et al., 
demonstrated that all three miRNAs were differentially expressed in MSI versus MSS 
CRC by 1.5 fold or more.  Whether the differential patterns of miRNA expression 
between the two cell lines is due to DNA methylation is a matter of question. 
However if this may be the case, it would explain at least in part the differences that 
have been recognised in the SW1116 cells versus the DLD1 cells.  
When comparing the responsiveness of each miRNA to the DNA demethylating 
agent, it is evident that miR-145 is most susceptible to DNA demethylation, followed 
by miR-143 and then miR-133b. This pattern is consistent regardless of the stage of 
the cancer cell line and therefore it may be assumed that the miRNA regulation 
occurs in the same manner in both the early and late stage CRC cells, with the likely 
cause being DNA methylation.   
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2.4.5 The stage specific effect of histone acetylation on the expression of 
miRNAs  
  
In the early stage CRC cells, all three miRNAs were induced by over 3 fold, following 
a 24 hour treatment with TSA. The miRNAs were also upregulated by DMSO by 
approximately 2 fold. Overall a net upregulation by 0.82, 1.85 and 2.11 for miR-133b, 
miR-143 and miR-145, respectively can be seen.  In comparison TSA does not seem 
to induce miRNA expression in the late stage CRC cell line, showing slight levels of 
downregulation. This trend was also evident in the DMSO carrier control in DLD1 
cells, for miR-143 and miR-133b and with only slight upregulation of miR-145. From 
this it would seem that the susceptibility of these miRNAs to the HDACi appears to 
be dependent upon the stage of the cell line.  
In the study by Zaman et al. in 2010, in which miRNA expression was detected after 
treatment of late stage metastatic prostate cancer cell lines with 5-Aza-2’-C, TSA 
and 5-Aza-2’-C plus TSA, miR-145 had only increased significantly with treatments 
containing 5-Aza-2’-C, while a minimal effect was shown for miR-145 expression 
upon treatment with TSA alone. This is similar to the results reported in this study, 
whereby late stage cells showed no effect on miR-145 when treated with TSA. 
However, significant upregulation of the miRNA is attained after treatment with 5-
Aza-2’-C.  Similarly, miR-143 was upregulated in TSA treated early stage SW1116 
cells. This finding agrees with raised levels of miR-143 reported in the non-invasive 
early stage MCF7 breast cancer cell line, upon treatment with TSA alone (Rhodes et 
al., 2012). In comparison, mir-133b expression increased in the Dukes’ stage C (late 
stage) cell lines, HT29 and SW620, following TSA treatment (Lv et al., 2015); 
thereby diminishing the correlation between the susceptibility of the miRNAs to TSA 
and cell staging. 
In studies where tumours were treated with HDACi’s, researchers became aware of 
a phenomenon in which cells would acquire resistance to the HDACi (Fedier et al., 
2007; Dedes et al., 2009). Imesch et al. in 2009 had further determined that 
resistance to TSA in colon cancer cells is caused specifically by a deficiency in the 
MLH1 gene, as the acquired resistance was only present in MSI cells.  As mentioned 
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previously the MLH1 gene is involved in DNA repair and its silencing by promoter 
hypermethylation characterises MSI cells. Resistance to TSA in MSI colon cancer 
cells was also accompanied with a loss in the accumulation of histone acetylation, 
lack of p21 induction and reduced apoptotic ability (Imesch et al., 2009). In the 
present study, this could potentially explain why TSA had no effect on miRNA 
expression, as the loss in histone acetylation would ultimately not allow for the re-
expression of silenced tumour suppressor genes due to enduring condensed 
chromatin formation. Moreover, the DMSO treated DLD1 cells lacked a response to 
TSA, unlike the DMSO induced miRNA expression in the SW1116 cells. It may be 
that DLD1 cells could be resistant to TSA at the concentrations used in this study. A 
relationship between DMSO and miRNA expression in MSI cells has not as yet been 
elucidated and may merit further investigation.  
2.4.6 Comparison of DNA demethylation versus histone acetylation on 
expression of miRNAs 
 
In the early stage CRC cell line SW1116, DNA demethylation seems to have a 
moderate influence on the expression of miRNA, this taking into account the 
expression of all three miRNAs post-treatment with the low dose 5-Aza-2’-C. MiRNA 
expression levels increased significantly in the late stage DLD1 cells for all miRNAs. 
A higher frequency of promoter DNA hypermethylation of all three miRNAs is a 
plausible justification of the increased induction of the miRNAs in DLD1 cells. This 
may well relate directly to the adenoma to carcinoma sequence postulated by 
Fearon and Vogelstein in 1990, which alluded to the accumulation of genetic and 
epigenetic alterations in a stepwise manner in the transformation from normal colon 
epithelium to adenocarcinoma. More specifically, an accumulation of DNA 
methylation through the transformation process is highlighted in this model. Thus it 
follows that DLD1 late stage CRC cells have a higher degree of DNA methylation 
than SW1116 cells. This could explain the tendency of the miRNAs to be more highly 
induced in DLD1 cells compared to SW1116 cells when treated with the DNA 
demethylation agent. This concept is further supported by Frigola et al. (2005) who 
demonstrated that carcinoma cells contained increased hypermethylation levels 
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compared to adenomas. Further to this, several tumour suppressor genes were 
shown to be more frequently methylated in advanced stages of colon cancer; p16 
methylation occurs more in Dukes’ stage C and D than in Dukes’ stage A and B  (Yi 
et al., 2001); CDKN2A hypermethylation is more prevalent in Dukes’ stage C (Maeda 
et al., 2003); DKK1 is selectively hypermethylated in advance CRC neoplasms 
(Aguilera et al., 2006); and miR-143 was also proven to be expressed at its lowest 
level in advanced stage cancer associated with lymph node metastasis (Qian et al., 
2013) . In addition miR-133b had lower expression levels in late as compared to 
early stages of cancer (Duan et al., 2013).   
In the present study, when compared to 5-Aza-2’-C treated SW1116 cells, TSA 
shows comparable induction of miRNAs in the early stage CRC cell line. However 
when evaluating the effect of 1µM 5-Aza-2’-C versus 300nM TSA in late stage CRC, 
there is a marked difference in the transcriptional induction of all three miRNAs. 
From these results it can be inferred that DNA methylation seems to play a more 
influential role in the regulation of miRNAs in the later stages of CRC, as discussed 
above.  However in contrast histone acetylation plays a moderate role in early CRC, 
while on its own does not seem to have an influence during the later stage of CRC. 
In this study, although the differences between the two stages were sought, it must 
however also be considered that the genotypes differ between the two cell lines.  
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Chapter 3: COMPUTATIONAL TARGET PREDICTION 





With over a thousand miRNAs identified so far and with each miRNA potentially 
targeting up to a hundred target genes each, it is not surprising that miRNAs regulate 
over 50% of mammalian protein coding genes (Friedman et al., 2009) exhibiting 
widespread functions in critical cellular processes. It is thus a vital task to identify 
and validate their targets to further understand the roles that each miRNA plays in 
regulating critical cellular processes and henceforth the development of diseased 
states upon their de-regulation. Identification of miRNA targets is contingent on 
sequence complementarity between mature miRNA sequences and the 3’ UTR of 
mRNA transcripts. Basic alignment tools, such as BLAST, lack in their ability to align 
short sequences such as miRNAs, thus motivating the development of specific target 
prediction algorithms. Almost perfect complementarity between mature miRNA 
sequences and their respective targets in plant cells allows for a simple and easy 
prediction (Voinnet et al., 2009). In stark comparison however, the imperfect 
complementarity displayed by animal/metazoan mature miRNAs to their targets 
posed a challenging task in the miRNA target prediction field. Consequently, this has 
led to the development of sophisticated computational algorithms to assist in the 
prediction of putative miRNA targets. In silico miRNA target prediction is a rapidly 
evolving field in miRNA research with increasing amounts of bioinformatic tools 
becoming available.  There are several parameters that are considered in the 
algorithms based on a number of principles of miRNA target recognition which are 
elaborated below.  
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3.1.1 Principals of miRNA target recognition 
 
3.1.1.1 Sequence complementarity  
 
miRNA recognition of a target was first discovered when it was found that the miRNA 
lin-4 regulates the expression of lin-14 in C.elegans (Wightman et al., 1993). This 
study also determined that the 3’UTR of lin-14 was sufficient to confer this regulation 
pattern. In 2004, Doench and Sharp had determined that the 5’ end of the miRNA 
was crucial for the repression of its target while the 3’ end had minimal value. It has 
also been shown that targets with the same sequence from nucleotides 2 to -7 of the 
5’ end of the miRNA share the same targets. This region from nucleotides 2 -7 of the 
5’ end of the miRNA has further been described as the “seed” region and requires 
strict Watson-Crick pairing in the miRNA-target duplex. The majority of miRNA target 
sites have perfect complementarity with the seed region. These sites deemed 
“canonical binding sites” are further categorised by three types (depicted in Fig 3.1 
A). The 7mer-A1 site contains complementarity to the seed region and has an 
adenine at the position corresponding to position 1 of the 5’ miRNA end. It is thought 
that the adenine in this position increases the target recognition efficiency (Lewis et 
al., 2005).  The 7mer-m8 site consists of complete seed region complementarity to 
its target, in addition to complementary base pairs at position 8 flanking the seed 
region.  The third canonical binding type termed 8mer, consists of the flanking 
adenosine in the target site corresponding to position 1 of the miRNA and has 
complementarity to position 8 flanking the miRNA seed region. There are some sites 
with perfect pairing to the seed region only. These 6mer sites are however 
associated with reduced efficiency and are only marginally available (Figure 3.2 B). 
The efficiency of site binding is ranked where 8mer > 7mer-m8 > 7mer-A1 > 6mer 
(Nielsen et al., 2007; Grimson et al., 2007). Target binding to the 3’ end of the 
miRNA also occurs and in these instances is thought to enhance the binding 
efficiency of the seed region pairing. These sites have 3’ supplementary binding with 
perfect seed matches (Figure 3.3 C). Mismatches and imperfect seed region pairing 
are also tolerated in some efficient binding sites. In these cases the mismatch in the 
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seed region is compensated for by extensive 3’ binding. 3’ compensatory binding 
seems to be preferentially located around nucleotides 13-16 (Figure 3.4 D). G:U 
wobbles have also been recognised in seed regions,  wherein a guanine is allowed 

















Figure 3.1 : Canonical miRNA-target binding types. 
Experimental evidence has determined three defined types of 
miRNA-target binding based on partial hybridisation of miRNA to 
target. A) perfect complementarity to the seed region is a minimal 
requirement for 5’ dominant binding types. An Adenine in position 
1 allows for preferential binding (Adapted from Bartel, 2009). 
 
7mer-A1 site – Seed match + A at position 1 
 
ORF ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・  N N N N N N A ・ ・ ・ ・ ・ ・ Poly(A) 
                                                                                |  |   |   |   |   |  | 
                             N N N N N N N N N N N N N N N N N N N N N         5’ miRNA 
                                                                           8  7 6  5 4  3  2 1 
                                                                                   Seed 
7mer-m8 site – Seed match + match at position 8 
 
ORF ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・N  N N N N N N ・ ・ ・ ・ ・ ・ ・ Poly(A) 
                                                                          |   |  |   |  |   |   | 
                          N N N N N N N N N N N N N N N N N N N N  N         5’ miRNA 
                                                                          8  7 6  5  4 3  2 1 
                                                                                 Seed 
8mer site – Seed match + A1 and m8 
 
ORF ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・    N N N N N N N A ・ ・ ・ ・ ・ ・ Poly(A) 
                                                                          |   |  |   |  |   |   |   | 
                          N N N N N N N N N N N N N N N N N N N N N          5’ miRNA 
                                                                          8  7 6  5 4  3  2 1 
                                                                                   Seed 
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      6mer site – Seed match  
ORF ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ N N N N N N ・ ・ ・ ・ ・ ・ Poly(A) 
                                                                               |   |   |  |  |   | 
                             N N N N N N N N N N N N N N N N N N N N N         5’ miRNA 
                                                                           8  7 6  5 4  3  2 1 
                                                                                   Seed 
 
Figure 3.2 : Marginal binding sites. 6mer sites contain perfect 
binding to the seed region only. These sites are the least common 
binding site (Adapted from Bartel, 2009).  
 
 
3’supplementary site – Seed match with supplementary pairing 
                               Supplementary    1-5 nt            Seed 
                                      pairing           loop              match 
ORF ・ ・ ・N  N  N  N  N  N  N  N ・ 
・
 
・ N  N  N  N  N  N  N ・ ・ ・ ・ ・ ・ ・ Poly(A) 
                               |    |   |    |    |    |                 |   |    |   |    |    |    | 
            N  N  N  N  N  N  N  N  N  N  N  
N
  N N  N  N  N  N  N  N  N      5’ miRNA 
                                 16 15 14 13                    8  7  6   5   4   3  2  1 
                                                                                     Seed 
Figure 3.3 :  3’ Supplementary binding site.  Binding of the 
mRNA to the 3’ end of the miRNA with a characteristic bulge in 















Figure 3.4 : 3’ compensatory site. A mismatch in the seed 
region can be compensated for by extra binding at the 3’ end of 
the miRNA (Adapted from Bartel, 2009). 
3’ compensatory site – Seed mismatch with compensatory pairing 
                                                                                                          
                             Compensatory       1-5 nt                 Seed 
                                      pairing           Loop               mismatch 
ORF ・ ・ ・ N  N  N  N  N  N  N  N ・ 
・
 ・  N  N   N 
 N 
 N  N  N  A ・ ・ ・ ・ ・ ・ Poly(A) 
                        |    |   |    |   |    |   |    |                  |    |    |         |   |    | 
              N  N  N  N  N  N  N  N  N  N N  
N
  N   N  N  N  N   N  N  N  N      5’ miRNA 
                                                                          8   7  6   5   4   3  2   1 
                                                                                        Seed 
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3.1.1.2 Conservation of miRNA-target interactions 
 
Considering conservation of miRNA-target interactions between orthologous 3’UTR 
sequences from several species significantly reduces the number of false positive 
predictions in bioinformatic target prediction programs. It has been of the notion that 
mammalian target sequences are retained through evolution due to selective 
pressure and that by comparing the 3’UTR of orthologous sequences allows for a 
more efficient miRNA target prediction. Early studies recognised that seed regions 
matched between orthologous sequences of flies and worms (Stark et al., 2003). 
Lewis et al. (2003) highlighted that about a third of human genes contain conserved 
targets of miRNAs. Subsequently, this volume increased to more than 60% of protein 
coding human genes under selective pressure to retain sites in the 3’ UTR as targets 
for miRNAs (Friedman et al., 2009). Despite the overwhelming level of conservation 
observed, there are still a considerable number of non-conserved sites that will not 
be identified with algorithms being highly dependent on alignment with orthologous 
sequences. A target prediction strategy relying on stringent conservation would fail to 
identify any non-conserved sites that may have developed through selection events. 
It is therefore important to combine conservation analysis with other principles of 
binding for a more precise prediction.  
 
3.1.1.3 Thermodynamics of miRNA:target binding  
 
The likelihood of a miRNA binding to its target appears to rely on the thermodynamic 
stability of duplex formation. This essentially denotes that the net energy required for 
the formation of the miRNA:mRNA duplex impacts the probability of the duplex 
interaction. The change in free energy (ΔG) is calculated as the difference between 
the energy spent on opening the mRNA target site and the energy gained by the 
formation of the miRNA-miRNA duplex formation (Kertesz et al., 2007). A lower 
energetic cost is generally indicative of the physiologic interaction. The RNA 
secondary structure influences the free energy required for the structure to unfold, as 
illustrated in Figure 3.5. Therefore programs that predict the secondary structure and 
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energy required to unfold the 3’UTR sequence are both incorporated in target 
prediction algorithms (Ding et al., 2004; Lorenz et al., 2011; Zuker et al., 2003).  
 
 
Figure 3.5: Free Energy of binding. Areas of complementary 
base pairing have a lower net energy than areas that are not 
bound. This principle is considered when measuring the free 
energy of binding of a miRNA to its target.  
 
3.1.1.4 Target site accessibility  
 
The accessibility of the mRNA target site to the miRNA seed region has an effect on 
the association and dissociation to and from the RNA Induced Silencing Complex 
(RISC). When assessing this component in computational prediction programs only 
the mRNA target site accessibility is considered as the mature miRNA is already 
lodged into the RISC, in a formation that exposes the seed region to its targets. The 
accessibility of the mRNA target is dependent upon the secondary structure of the 
sequence and also to the free energy of unbinding, as described above. Another 
factor to consider is the local AU content in the mRNA target. A higher AU content 
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allows for a weaker mRNA secondary structure making the target amenable to 
unfolding and therefore increasing the access of the target to the miRNA-RISC 
complex (Grimson et al., 2007). 
 
3.1.1.5 3’UTR context  
 
The position of the target site within the 3’UTR influences the efficacy of miRNA 
mediated silencing of the target (Grimson et al., 2007). It is required that the position 
of the target site is within 15nt of the stop codon, a feature which may have evolved 
due to the placement of the ribosomal complex. The length of the 3’UTR also affects 
the position of the target site whereby in short 3’UTRs the target sites are most likely 
in the 5’ end of the 3’UTR and in long 3’UTRs the target site is generally not located 
in the centre, due to inaccessibility to the silencing complex. It has also been shown 
that some mRNA target site have multiple sites for the miRNA which seems to 
enhance the level of repression (Doench et al., 2003; Brennecke et al. 2005; 
Grimson et al., 2007). Target sites that are located close together have also 
demonstrated synergistic behaviour by revealing optimal downregulation when two 
target sites are between 13 – 35 nt apart (Saetrom et al., 2007). Furthermore, an AU 
rich nucleotide composition of the sequence flanking the target site is also a feature 
of efficient miRNA target sites, especially owing to its contribution to site 
accessibility, as discussed above.  
 
3.1.2 Choosing the right target prediction tools 
 
Although the exact mechanisms of miRNA targeting is not yet fully elucidated, the 
aforementioned principals, which have been experimentally validated, have provided 
researchers with parameters to exploit and incorporate in the development of 
computational miRNA target prediction tools.  The first programs developed took 
advantage of sequence complementarity of the target to the miRNA seed region, 
which the majority of miRNA target prediction tools still utilise to date. Conservation 
became a key consideration when programs that used a conservation parameter had 
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a lower rate of false positives (Lewis et al., 2005). Since each computational 
program applies the different miRNA binding features with different weighting scales 
and combinations, the results from each program do not exactly match the next, 
therefore making it difficult to assess which program performs best. To assist in 
estimating the performance of the algorithms, programs are assessed according to 
two key factors, specificity or the “true negative rate” and sensitivity, referred to as 
the “true positive rate” (Lalkhen & McCluskey, 2008). The “true negative rate” 
(specificity) essentially refers to the number of non-targets correctly predicted not to 
be targets of the miRNA; whilst the “true positive rate” (sensitivity), reflects the 
number of validated targets that are correctly predicted as targets by the miRNA 
prediction program. Certain components which are included in the algorithm will 
have an influence on specificity and/or sensitivity; for example, by implementing 
stricter thresholds for conservation or thermodynamic stability the specificity may be 
increased, while the sensitivity may be compromised significantly. Essentially a 
trade-off between specificity and sensitivity is required to achieve optimal 
performance of the program. A reliable method of assessing the performance of the 
algorithm is by plotting sensitivity/specificity pairs for each prediction at different cut 
offs on a ROC curve (Figure 3.6), which is the plot of sensitivity versus 100-
specificity (Lalkhen & McCluskey, 2008). The closer the curve is to the upper left 
corner, the more reliable the test is. The Area under the Curve (AUC) is the measure 
used to quantify the reliability of the program. 
  













Figure 3.6: ROC (Receiver Operating Characteristic) Curve. 
The blue line depicts the plot of an excellent program. The red line 
depicts a good performance while the black dashed line depicts a 
random (non-specific) performance. A larger “area under the 
curve” or AUC would indicate a more reliable 
test/program/algorithm (Lalkhen & McCluskey, 2008). 
 
3.1.3 Functional analysis of putative targets 
 
Prediction of miRNA targets, with the use of computational tools, provides a lengthy 
list of potential targets to be validated further. There are several methods used to 
determine if the potential targets are valid targets. These methods typically rely on 
three premises of miRNA/mRNA target relationships: 
1. The first and most overt premise is that the miRNA reduces the expression of 
the target by binding to the 3’UTR (Bartel, 2009). Validation using this method 
involves the use of a reporter plasmid in which the 3’UTR of the target gene is 
cloned downstream of a luciferase or green fluorescent protein (GFP) open 
reading frame. Once the recombinant plasmid is transiently transfected into a 
neutral host cell along with the miRNA of interest, the levels of fluorescence is 
assessed in cells with miRNA versus those without the miRNA.  Undoubtedly 
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in the case of a true target, the fluorescence level would be decreased in the 
cells hosting increased levels of miRNA. 
2. The second avenue of validation is based on the premise that if an mRNA is a 
target of a miRNA, then the two should be co-expressed in a cell in order for 
the miRNA to regulate the mRNA target (Kuhn et al., 2008). Using this 
premise the levels of miRNA and mRNA are assessed for co-expression 
using Northern blots or quantitative PCR. In situ hybridization is also used to 
confirm co-expressed miRNA and mRNA sets.  
3. The third premise on which miRNAs are being validated relies on the fact that 
ultimately the miRNA would affect the levels of the biological product of 
mRNA, that is, the protein (Thomson et al., 2011). Validation of miRNA 
targets using this premise involves the transfection of anti-miRNA or precursor 
miRNAs into a homeostatic cell and then assessing the levels of protein within 
the cell approximately 24-48 hours after transfection.   
3.1.4 Objectives 
 
To further understand the role that the putative CRC-related tumour suppressor 
miRNAs play in cancer, an imperative task is to identify its targets. This chapter 
describes and discusses the identification of putative targets for miRNA-143, -145 
and -133b through the following objectives:   
 By selecting appropriate bioinformatics tools to predict targets for each 
miRNA 
 Next, developing a curating strategy to filter predicted targets for further 
functional analysis  
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3.2 Methodology and Materials 
3.2.1 Computational tool selection 
As discussed above, it is clear that each bioinformatic tool will yield results that may 
differ to the next. In this study three tools were selected to predict targets for the 
miRNAs of interest. The tools were selected to encompass the various principles of 
miRNA-target binding. Also, a key consideration is the sensitivity and specificity of 
each program which justifies the reliability of the results retrieved through the 
program. The motivation behind using three different target prediction programs lies 
upon the hypothesis that if all three programs predict the same target by using 
different algorithms, then it is more likely to be a true target. Only targets that were 
predicted by all chosen programs were considered for further filtering. The features 
of each program are described below:  
3.2.1.1 Program 1: TargetScan v5.1 (http://targetscan.org) 
 
TargetScan utilises a rule based algorithm that first searches for full seed region 
complementarity and thereafter extends the search to regions outside the seed 
region (approximately 21-23 nucleotide fragments) until a mismatch is detected. 
Classifications are then made on the length of perfect complementarity and an 
adenine at position 1. Imperfect seed matches with 3’ compensatory pairing are also 
considered in this algorithm to accommodate G:U wobbles. The complementary 
regions are then analysed by the RNAfold program to determine the minimum free 
energy secondary structure. Conservation is considered in this algorithm by aligning 
orthologous 3’UTRs from up to 5 different species and then determining if the seed 
region is located in an island of conservation. The resulting score is calculated per 
3’UTR. The scoring relies on several parameters; the type of seed matching, any 
pairing that occurs outside of the seed region, AU content upstream and downstream 
of the seed region and the overall distance of the site to the nearest untranslated 
region (Lewis et al., 2005). 
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3.2.1.2 Program 2: PicTar – Probabilistic Identification of Combination of 
Target sites (http://pictar.bio.nyu.edu) 
 
Unlike TargetScan, PicTar is a data-driven algorithm, rather than a rule-based one. 
This essentially means that prediction of miRNA targets, using this algorithm, is not 
only reliant on a given set of requirements but rather on available data. The program 
searches for near to full complementarity of conserved 3’UTRs.  The alignment 
across up to 8 vertebrate species is an important consideration in the program to 
reduce the number of false positives. Once the complementarity and conservation 
checks are complete, it then uses RNAHybrid to calculate the energy spend of 
miRNA-3’UTR duplex formation. The program uses energy-cutoffs for different types 
of binding. Therefore a seed region with a mismatch may be selected as long as it is 
within a specified energetic range.  Predicted targets are then scored using a Hidden 
Markov Model (HMM) which is based on a Bayesian classifier model. This statistical 
model is used to analyse chains or sequences in which the rules governing the 
production of the chain is not known. By “studying” experimentally validated datasets 
the model uses a maximum likelihood approach to determine the probability of an 
observation occurring (Krek et al., 2005; Lall et al., 2006). 
3.2.1.3 Program 3: DIANA-MicroT v3.0 (http://diana.pcbi.upenn.edu) 
 
DIANA MicroT v3.0 requires strict seed region base pairing and shows preference 
for 7mer Watson-Crick paired sites. 6mer sites and seed matches with G:U wobbles 
are considered if supplementary 3’ binding of miRNA is present, or if binding energy 
is favourable. Thermodynamic parameters are considered by a 38nt window 
progressively scanning across a 3’UTR sequence subsequently using a modified 
dynamic programming approach to calculate free energies of potential binding sites 
at each step. Conservation is also included in the final scoring, however a non-
conserved site may also be considered. Once the target sites are identified they are 
compared to targets identified from mock sequences and a signal-to-noise ratio and 
precision score is obtained for each site. Mock sequences are essentially random 
sequences designed per miRNA that have the same number of seed sites per 
  
  84 
 
3’UTR. These sites are not biologically functional and therefore the ability of the 
program to recognise the difference allows for the SNR to be determined (Kiriakidou 
et al., 2004). 
3.2.2 Strategic curation of predicted targets 
Relying only on the aforementioned computational programs to identify miRNA 
targets would be premature. Validation of miRNA targets is a lengthy and relatively 
expensive procedure and therefore additional analysis and curation of the predicted 
targets should be completed to filter the potential targets and essentially reduce the 
number of false positives. In this study, only targets that were predicted across all 
three programs were considered for the strategic curation developed for this study. 
As miR-145, miR-143 and miR-133b seem to commonly be downregulated in CRC, 
the hypothesis was made that ultimately the combination of the three miRNAs would 
affect pathways related to the tumourigenesis process and potentially in CRC 
development. Under this inference the targets identified per miRNA, and that were 
predicted by all three programs, were loaded into DIANA mirPATH v1, a program 
that identifies the KEGG pathway enrichment of the combined miRNA predicted 
targets. KEGG, the Kyoto Encyclopedia of Genomes and Genes, is a collection of 
manually transcribed pathways representing the current knowledge of molecular 
systems. Once the list of overrepresented pathways were identified, all miRNA 
targets within these pathways were outlined. Targets linked to more than one CRC 
identified pathway were weighted more and therefore ranked higher than those only 
associated with one pathway. Subsequent systemic literature analyses was 
conducted for all filtered targets to determine a strong reference to CRC, most 
specifically an increased expression which demonstrates an antagonistic relationship 
to the downregulated miRNA recognised in CRC.  
Figure 3.7 illustrates the manual curation methodology used to streamline the 
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PicTar TargetScan 5.1 DIANA-MicroT v 3.0 
Hsa-miR-143 (3p and 5p) 
Hsa-miR-145 (3p and 5p) 
Hsa-miR-133b 
DIANA mirPATH 
KEGG pathway enrichment 
Identify CRC pathways implicated by the predicted 
targets of the three miRNAs.  
List of targets per miRNA 
within the CRC identified 
pathways  
Through a literature search, identify the 



















Figure 3.7: Target prediction methodology and selection of 
targets for functional analysis. *List of targets within CRC 
identified pathways were further ranked according to number of 
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3.2.3 Functional Analysis of selected putative targets 
3.2.3.1 Cell culture 
 
For a reliable assessment of miRNA target genes, a cell line without potentially 
downregulated miR-143, -145 and -133b was used. In this case the HET1A cell line 
was utilised. This cell line is derived from a normal human oesophagus and has 
been shown to demonstrate normal levels of the miRNAs in question. Aseptic 
techniques were used in the cell culturing procedure as described previously in 
Chapter 2.2. The cells were however grown in a special growth medium, BEBM 
(bronchial epithelial basal medium) obtained from Lonza.   
3.2.3.2 Anti-miR transfection 
 
Once the HET1A cells had reached 80% confluency, the cells were washed with 
PBS (Sigma Aldrich) and transfected with Anti-miR™ 143, 145 and 133b oligomers 
(Ambion) using the siPORT NeoFX Transfection agent (Ambion), as per 
manufacturer’s instructions. Prior to the experiment, the concentrations of the Anti-
miR™ oligomers and the transfection reagent were optimised to ensure optimal 
transfection. Anti-miR™ oligomers were used at a concentration of 30nM and the 
siPORT NeoFX transfection reagent was used at a concentration of 3µL in the 
treated cells. The transfection mix was incubated with the HET-1A cells for 24 hours. 
Three controls were included to identify confounding effects from other reagents and 
to assess the effects of the Anti-miR™ with confidence. The first control was an 
untransfected cell line, cultured as per normal cell culture procedures, in the absence 
of transfection. In the second control, cells were treated with the transfection mixture 
lacking the transfection reagent (siPORT NeoFX transfection agent) and only the 
Anti-miR™. The third control involved transfection with Anti-miR™ miRNA Inhibitor 
Negative Control #1 (Ambion) which is a random oligomer that is not biologically 
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3.2.3.3 Fluorescence microscopy 
  
Following transfection for 24 hours with the transfection mixture or the controls, cells 
were harvested by centrifugation and thereafter the pellet was resuspended in 6mL 
of BEBM (Lonza), of which 1 mL was re-suspended in 7mL fresh room temperature 
BEBM. Prior to harvesting the cells, glass coverslips were immersed in a 70%v/v 
ethanol solution, then heat sterilised by flaming and placed in petri dishes. The 
resuspended cell mixture was carefully transferred on-to the glass coverslip to 
ensure full coverage, without spilling over into the petri dish. The coverslips were 
then incubated at 37˚C with 5% CO2 for 5 hours to ensure cell adherence to the 
surface of the coverslip. Once the cells were adhered to the glass surface, fresh 
BEBM was added to the petri dish and maintained overnight for the cells to grow on 
the coverslip surface.  
After overnight incubation, the next step involved fixing of the cells to the coverslip. A 
3%v/v formaldehyde solution was prepared by mixing 3mL formaldehyde (Univar) in 
33mL PBS which was used as a fixative solution. Medium was removed from the 
petri dish containing the seeded coverslip. The cells were washed in PBS three 
times to remove excess growth medium. After this, the fixative solution was added to 
the petri dish containing seeded coverslips and kept at room temperature for 10-15 
min. Fixative was aspirated off and safely discarded in a fume hood drain. The 
coverslips were washed three times with PBS to remove excess fixative solution. 
Finally, the fixed coverslips were then immersed in PBS solution in petri dishes, 
sealed with Parafilm® and stored at 4˚C overnight.     
Prior to adding the primary antibody to the fixed cells seeded on coverslips, a 
0.5%w/v solution of BSA (bovine serum albumin)/PBS was prepared.  125µL Triton 
X-100 detergent was added to 25mL BSA/PBS. PBS was removed from the petri 
dishes containing fixed seeded coverslips that were stored overnight. The 0.5%v/v 
Triton X-100 detergent solution was added to the petri dish and kept at room 
temperature for 10 minutes. Triton X-100 is a non-ionic surfactant which 
permeabilises the cell membrane, subsequently allowing the primary antibody entry 
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into the cell. Once the cell membrane was permeabilised the cell-free side of the 
coverslips were dried without disturbing the cell monolayer and placed cell surface 
up on a dry microscope slide. A 1:100 dilution of primary antibody in 0.5%v/v 
BSA/PBS was then prepared and 100µL of the primary antibody solution was added 
to the coverslip.  The coverslips and slides were then transferred to an airtight 
container that was kept humid with wet filter paper and stored at 4˚C overnight.   
Table 3.1 indicates the primary antibody employed for each miRNA gene target.  
Prior to staining with the secondary antibody, three beakers were filled with 
autoclaved PBS. The cover slips containing primary antibody were removed from the 
microscope slide with forceps and drained of liquid on paper towel to remove the 
primary antibody solution. The coverslips were then sequentially dipped 10 times in 
each of the three beakers of PBS before being dried again and transferred to the 
clean microscope slide, cell side uppermost. A 1:200 dilution of secondary antibody 
in 0.5%v/v BSA/PBS was then prepared and 100µL of the secondary antibody 
solution was added to the coverslip. The slides were then transferred to the airtight 
humid container and stored in a dark cupboard for 1 hour at room temperature 
(25˚C).  The relevant secondary antibodies used to detect each primary antibody are 
indicated in Table 3.1 below.  








KRAS mouse monoclonal 
IgG2a (Santa Cruz 
Biotechnologies) 
AlexaFluor® 568 conjugated 
anti-mouse (Life Technologies) 
Anti-miR™ 
145 
FZD7 goat polyclonal IgG 
(Santa Cruz Biotechnologies) 
AlexaFluor® 568 conjugated 
anti-goat (Life Technologies) 
Anti-miR™ 
133b 
ß-TRCP goat polyclonal IgG 
(Santa Cruz Biotechnologies) 
AlexaFluor® 568 conjugated 
anti-goat (Life Technologies) 
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Once the secondary antibody staining was complete, the nucleus of the cell was 
then stained with DAPI, 4', 6-diamidino-2-phenylindole (Boehringer Ingelheim). DAPI 
is a stain containing blue fluorescence which specifically binds to AT-rich areas of 
double stranded DNA (Kapuscinski, 1995). Coverslips were drained of the secondary 
antibody mixture and dipped serially in three beakers of autoclaved PBS, ten times 
each, in order to remove excess secondary antibody mixture. DAPI was diluted 
1:10000 in PBS and added to the coverslips and transferred back to the clean 
microscope slides. The slides were returned to the airtight humid container and 
stored for 30-45 min in a dark cupboard at 25˚C.  
Once DAPI staining was completed, the coverslips were drained and rinsed serially 
in PBS before being transferred cell surface down onto a new microscope slide using 
Gel Mount ™ aqueous mounting medium (Sigma-Aldrich). The mounted coverslips 
were left to dry and then stored at 4˚C, until viewed under the Olympus IX71 inverted 
fluorescence microscope and Zeiss LSM 780 laser scanning microscope, using a 
63x objective. 











Figure 3.8: Predicted number of target genes per miRNA.   
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The mature miRNA sequences for hsa-miR-143-3p, hsa-miR-143-5p, hsa-miR-145-
3p, hsa-miR-145p and hsa-miR-133b were submitted into the target prediction 
algorithms TargetScan 5.1, PicTar and DIANA-Micro T v3.0, as described in section 
3.2.1. Overall miR-143 was predicted to have the least number of targets by all three 
programs, where TargetScan 5.1 predicted 263 conserved targets, PicTar predicted 
239 targets and DIANA-Micro T v3.0 predicted 259 target genes. For TargetScan 
5.1, there were 272 conserved target sites and 134 poorly conserved target sites 
within the 263 target genes. Of the 259 genes predicted by DIANA-MicroT v3.0, 
there were 307 target sites predicted within these genes.  MiR-145 yielded large 
numbers of miRNA targets, most specifically when using TargetScan 5.1 and 
DIANA-microTv3.0 predicting 528 and 471 target genes. Although PicTar had 
predicted a lower number of targets for miR-145 compared to the other two 
computational programs, this number (326) is still higher than the number of target 
genes predicted for miR-143. TargetScan 5.1 predictions for miR-145 resulted in 585 
conserved sites and 174 poorly conserved sites within the 528 target genes. For 
DIANA-MicroT v3.0 a total of 502 target sites were identified. MiR-133b had also 
produced large numbers of predicted targets from each program. Some 502 target 
genes, of which were 530 conserved sites and 80 were poorly conserved sites, were 
identified from TargetScan 5.1, a total of 471 targets were identified from PicTar and 
399 targets (421 target sites) were identified with DIANA-MicroTv3.0.  
These results demonstrate that each program yields differential sets of target genes 
and sites per miRNA. All three programs derive the miRNA mature sequences from 
mirBase and use RefSeq sequences to map 3’UTRs. The differences in predictions 
are purely as a result of the different algorithms and weighted scoring and thresholds 
for the principles of miRNA-target binding considered by each program. The resulting 
dataset of almost 3500 miRNA targets required further curation and filtering to make 
the data more meaningful.   
The 3458 targets predicted for all miRNAs were then submitted into the DIANA 
mirPATH v1 algorithm. The resulting KEGG pathways enriched by the combined 
predicted targets for the three miRNAs were determined. Figure 3.9 below 
represents in histogram format the output of the pathway enrichment. It shows the 
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probabilities of the pathway association when assessing the union of all targets, 
those targets predicted for each miRNA per target prediction program and also the 



























Figure 3.9: KEGG pathway enrichment of the combined miRNA targets.  miR-143, miR-145 and miR-133b predicted 
targets from TargetScan, PicTar and DIANA MicroTv3.0 were transferred to DIANA mirPATH to obtain enrichment of KEGG 
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The top 25 significantly enriched pathways from the predicted miRNA targets 
illustrated in Figure 3.9 reveals that pathways potentially influenced by the combined 
expression of the three miRNAs fall within clearly recognizable categories listed 
below:  
 Cancer (Chronic Myeloid Leukaemia (CML), Colorectal Cancer (CRC), 
Pancreatic Cancer, Melanoma, Glioma, Prostate Cancer, Non-small cell lung 
cancer(NSCLC) 
 Growth signalling pathways (Wnt signalling pathway, TGF-beta signalling 
pathway, MAPK signalling pathway and Notch signalling pathway) 
 Cell-cell and cell-ECM interactions (Adherens Junctions, Regulation of actin 
cytoskeleton, Tight junction, Focal adhesion, Gap junction, ECM-receptor 
interaction) 
 Neuron signalling and related disease (Axon guidance, Amyotrophic lateral 
sclerosis (ALS), Neurodegenerative Disease) 
Of particular interest in this study, “Colorectal Cancer” was a KEGG pathway found 
to be enriched by the combined targets of the three putative tumour suppressor 
miRNAs. Additionally, several growth signalling pathways previously reported to be 
deregulated in CRC have also been enriched here with most of them listed within the 
Top 10 pathways enriched from the combined miRNA predicted targets. This 
information provides some indication of the involvement of these miRNAs in the 
development of CRC specifically through these pathways.  From these results, one 
could easily infer that these three miRNAs potentially regulate key CRC-related 
pathways and could possibly explain the relationship of the miRNAs in the 
development of CRC. However, as the target prediction programs are essentially just 
a prediction tool with percentages of false positive rates, these findings require 














Figure 3.10: KEGG Pathway enrichment of CRC-related 
pathways.   Combined targets of miR-143, miR-145 and miR-133b 
predicted using PicTar, TargetScan and DIANA MicroT. Obtained 
from DIANA MicroT V1.0 
 
Based on the DIANA mirPATH v1 output, the CRC-related pathways were ranked for 
significance according to the probabilities of the pathway being enriched by the 
miRNA targets (see Figure 3.10 above). The Wnt signalling pathway is the most 
enriched CRC related pathway followed by the TGF-beta signalling pathway, 
sequentially followed by “Colorectal cancer”, the MAPK signalling pathway and lastly 
a slight enrichment of the Notch signalling pathway.  All predicted targets that fell 
within these pathways were determined per miRNA and only those targets predicted 
across all three computational programs were listed for further analysis. Targets 
falling within more than one CRC-related pathway were ranked higher than those 
only linked to one; and those linked to a more significantly enriched pathway ranked 
higher than a less significant pathway. The filtered list of potential miRNA targets are 
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Table 3.2: List of potential targets per miRNA associated with KEGG 
CRC-related pathways. 
 
*Experimentally validated targets 
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A systemic literature search was conducted on each predicted target represented in 
Table 3.2. The search involved assessing gene or protein expression in CRC and 
their potential roles in CRC development. Most importantly however, evidence of 
oncogenic potential of the target was assessed. If the predicted gene is a true target 
of the miRNAs in question, then upon downregulation of the specific miRNAs, one 
could expect to see a resultant increased expression of the target in CRC. After the 
literature search was completed, the targets boxed in red in Table 3.2 were chosen 
for functional analysis due to their strong inference of an increased expression in 
CRC. A detailed view of the putative miRNA-target binding sites is described further.  
Three sites in the KRAS gene (ENSG00000133703) were predicted by all three 
programs as miR-143 targets. Two 8mer sites were conserved across several 
vertebrate species. A 7mer-1A site demonstrated poor conservation amongst aligned 
vertebrate orthologues. MiR-143-KRAS binding sites are depicted in Figure 3.11: 
Conserved sites: 
 
Poorly conserved site: 
 
Figure 3.11: miR-143 binding sites in the KRAS gene. 
Two 8-mer sites were predicted with the seed regions 
positioned at region 1602-1608 and 3647-3653 of the KRAS 
3’UTR.  
 
Within the FZD7 (ENSG00000155760) gene chosen as a potential miR-145 target 
for further functional analysis, a single 7mer-m8 site was predicted across all three 
computational programs. The seed region of the site is located at position 518-524 of 
the FZD7 3’UTR. MiR-145-FZD7 putative binding is depicted in Figure 3.12 below. 
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Figure 3.12: miR-145 binding site in the FZD7 gene.  A 
single 7mer-m8 site was predicted with the seed region 
positioned at region 518-524 in the FZD7 3’UTR. 
 
For miR-133b, the FBXW11 (ENSG00000072803) gene was selected as a putative 
target for further functional analysis. A single 7mer-m8 site wherein the seed region 
is located at position 1622-1628 of the FBXW11 3’UTR was predicted across all 
three computational target prediction programs used in this study. The miR-133b-
FBXW11 binding site is depicted below in Figure 3.13. 
 
Figure 3.13: miR-133b binding site in the FBXW11 gene. 
A single 7mer-m8 site was predicted with the seed region 
positioned at 1622-1628 in the FBXW11 3’UTR. 
 
In silico miRNA target prediction provided a platform to identify potential targets for 
each miRNA and the chosen targets were supported by scientific literature in relation 
to CRC development. In order to test the functionality of these potential targets, the 
protein levels were measured by immunofluorescence, before and after HET1a cells 


















Figure 3.14: Immunofluorescence confocal microscopy 
image of KRAS protein in Anti-miR™ 143 transfected 
HET1A cells. (A) KRAS is strongly expressed in the nucleus 
(N) and nuclear periphery extending into the cytoplasm, after 
miR-143 inhibition. B) Untransfected control. C) Negative 
control D) Transfection reagent control. Blue = nucleus (N), Red 
= KRAS protein (Original magnification of 63x) 
 
After HET1A cells were transfected with anti-miR-143 miRNA inhibitor and thereafter 
stained with anti-KRAS, it can be clearly seen in Figure 3.14 that KRAS expression 
appears to be intensely increased (A) when compared to the untransfected control 
(B), the negative control (C) and the TR control (D). Thus, the increased 
fluorescence representing KRAS protein expression appears to increase with 
decreased expression of miR-143. Moreover, this increase in expression is not due 
to the transfection reagent, but is specifically related to transfection with the anti-miR 
for miR-143. An antagonistic relationship is represented here between miR-143 and 
KRAS protein, which is indicative of a miRNA-target relationship. In anti-miR-143 
transfected cells KRAS is intensely expressed in the nucleus, the nuclear periphery 
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transfection, KRAS expression is sparsely located along the periphery of the nucleus 















Figure 3.15: Immunofluorescence confocal microscopy 
image of FZD7 expression in Anti-miR™ 145 transfected 
HET1A cells.  (A) FZD7 localises peri-nuclearly after miR-145 
inhibition B) Untransfected control. C) Negative control D) 
Transfection reagent control. Blue = nucleus (N), Red = FZD7 
protein (Original magnification of 63x) 
 
HET1A cells were transfected with anti-miR-145 miRNA inhibitor to decrease the 
expression of miR-145 and to determine the subsequent effect on the expression of 
FZD7. Figure 3.15 depicts the immunofluorescence staining of the cells with anti-
FZD7 before and after the transfection with anti-miR-145, revealing an 
overexpression of FZD7 (A), when compared to the untransfected cells (B). Although 
there seems to be a marginal increase in FZD7 expression upon transfection with 
the negative control sequence (C) and the transfection reagent control (D), there is a 
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is localised evenly in the cytoplasm of the cells that were not transfected with anti-
miR-145, however when transfected with anti-miR-145, there is intense nuclear and 















Figure 3.16: Immunofluorescence confocal microscopy 
image of FBXW11/ßTRCP expression in Anti-miR™ 133b 
transfected HET1A cells. (A) FBXW11/ßTRCP protein 
expression is increased in the nucleus and cytoplasm post miR-
133b inhibition.  B) Untransfected control. C) Negative control 
D) Transfection reagent control. Blue = nucleus (N), Red = 
FBXW11/ßTRCP protein (Original magnification of 63x) 
 
To assess the effect of miR-133b on the proteomic expression of FBXW11, HET1A 
cells were first transfected with anti-miR-133b miRNA inhibitor and then stained by 
immunofluorescence to detect FBXW11. Figure 3.16 demonstrates the expression of 
FBXW11 protein pre- and post-transfection with the anti-miR-133b inhibitor. MiR-
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the untransfected cells (B). FBXW11 localises primarily in the cytoplasm with 
marginal nuclear staining in the untransfected cells, however FBXW11 does not 
extend towards the plasma membrane. Upon miR-133b inhibition, FBXW11 is 
intensely localised to the nucleus and nuclear periphery, with a marginal increase in 
the cytoplasmic region. The negative control transfected cells (C) and the 
transfection reagent control cells (D) yield FBXW11 expression patterns similar to 
the untransfected cells and therefore the intense increase in FBXW11 expression 
and altered localization is a specific response to anti-miR-133b.    
3.4 Discussion  
Identifying miRNA targets manually can be a laborious and indirect process. With 
thousands of identified miRNAs each targeting over 100 target genes, an 
overwhelming task to identify all targets of identified miRNAs still continues despite 
the progress made in this field in the past two decades. Furthermore, methods to 
validate a target can be protracted and expensive, this requiring supplementary 
evidence before a potential target is selected for validation. Computational programs 
assist greatly in mining large datasets by using sophisticated algorithms to combine 
principles of miRNA-target recognition to identify targets in published transcriptomes. 
In this study computational target prediction programs were utilised to specifically 
predict gene targets of miR-143, miR-145 and miR-133b to further elucidate the role 
that these miRNAs play in CRC.   
3.4.1 Selection of miRNA target prediction tools 
The first objective of this chapter was to select appropriate computational tools to 
assist in predicting targets for three miRNAs under study.  TargetScan, PicTar and 
DIANA microTv3 were selected for this study based on their favourable scores in 
precision and sensitivity compared to other available algorithms (Summarised in 
Table 3.3). Despite the miRanda program exhibiting high levels of sensitivity 
(Sethupathy et al., 2006; Alexiou et al., 2009) in comparison to most other programs 
listed, it nevertheless yields exceptionally high numbers of false positives and was 
therefore not selected for the present analysis.   
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All three programs used in this study incorporate alignment with orthologous 3’UTRS 
as a key step. Witkos et al. (2011) had previously devised a strategy for miRNA 
target prediction in which the first step is to use programs considering conservation, 
particularly since these programs are associated with higher sensitivity and precision 
and essentially reduce the number of false positives. It is of the assumption that if a 
miRNA target is predicted by more than one program then it is more likely to be an 
appropriate target; and therefore only coinciding targets predicted across the three 
programs were considered valid here. 
The sensitivity and precision scores for DIANA MicroTv3, TargetScan and PicTar 
clearly demonstrated superior performance to other programs (summarised below in 
Table 3.3) and based on these values the programs were selected for the study.  A 
study by Baek et al., 2008 tested the performance of several miRNA target prediction 
programs by comparing proteomic changes with quantitative mass-spectrometry 
using SILAC (stable isotope labelled amino acids in cell culture), after altering the 
level of miR-223 in mice neutrophils. The correlation of their results to the targets 
predicted by several programs demonstrated superior performance of TargetScan 
and PicTar. Furthermore, the context score provided for each prediction in 
TargetScan was strongly related to protein downregulation.      
A similar correlation experiment was completed by Alexiou et al., (2009), whereby a 
modified SILAC method coupled with mass-spectrometry was used to detect 
proteomic changes in response to increased expression of 5 miRNAs in HeLa cells. 
When assessing their results in relation to those received from target prediction 
programs, PicTar, TargetScan and DIANA-microT exhibited the highest levels of 
sensitivity (10-12%) and specificity (~50%). 
A more recent study used benchmarked datasets to assess the performance of 38 
available target prediction programs. Owing to the availability of more validated 
targets the levels of sensitivity and specificity have increased for all programs, but 
the performance of DIANA-microT was particularly distinguished compared to all 
other programs (Fan & Kurgan, 2014). 
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 Table 3.3: miRNA target prediction program features and performance evaluations.  (Adapted from Witkos et al., 2011) 
    *Bold text indicates superior performance                                                                                                    
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3.4.2 Curating strategy to filter miRNA predicted targets 
 
Under the second objective of developing a curating strategy to filter predicted 
targets for further functional analysis, the DIANA mirPATH v1 tool was used to 
effectively mine the large dataset of almost 3500 miRNA targets and to determine 
the pathways and physiologic processes that are potentially influenced by the 
combined expression of the miRNAs through their targets. According to initial 
assumptions, CRC and related pathways were significantly enriched by the 
combined targets of the miRNA-143, -145 and -133b (Figures 3.9 and 3.10). To infer 
that the miRNAs have a direct effect on the pathways listed would be precipitous at 
this stage because the targets used for the enrichment analysis have not all been 
validated as yet. The results do however provide suggestions for the potential 
mechanisms in which the miRNAs could contribute to CRC tumourigenesis.  
MiR-143, -145 and 133b putative targets predicted through PicTar, TargetScan and 
DIANA-microT appear to be associated with KEGG pathways in four grouped 
categories. The first recognizable group involves several types of cancer; CML, 
CRC, Pancreatic Cancer, Melanoma, Glioma, Prostate Cancer and NSCLC. Further 
support for the relation of the three miRNAs to the cancers enriched through DIANA 
mirPATH v1 (pg 106) was obtained from the miRCancer database 
(http://mircancer.ecu.edu/), which is a collection of miRNA expression profiles in 
cancer types obtained from published literature via text mining in PubMed. Within the 
database there are 14 published articles on miR-143 downregulation in colon and 
CRC. In addition to the miRNAs involvement in several other cancers, evidence of 
miR-143 involvement in Glioma (1), malignant melanoma (1), Non-small cell lung 
cancer (2), pancreatic cancer (1) and prostate cancer (4) is available within the 
database. For miR-145, downregulation in colon/CRC  (15), Glioma (2), Non-small 
cell lung cancer (7), Pancreatic Cancer (2) and Prostate Cancer (5), amongst a 
variety of other malignancies, has been published and is available in the miRCancer 
database. MiR-133b, despite being less frequently reported in cancer, is involved in 
CRC (2) and Prostate Cancer (1) amongst other cancers in the database. Note that 
the numbers in the brackets relate to the number of published articles available in 
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the miRCancer database. These associations relate consistently to the enriched 
KEGG pathways within the Cancer category as depicted in Figure 3.9, providing 
further support to the reliability of the miRNA predicted targets. 
Several growth signalling pathways (Wnt, TGF-ß, MAPK and Notch signalling 
pathways) were also associated with the combined targets predicted for the three 
miRNAs.  CRC has been linked with each enriched pathway providing further hints at 
the role of the miRNAs in CRC development (Bienz & Clevers, 2000; Xu & Pasche, 
2007; Qiao & Wong, 2009; Grossi et al., 2014).  
When assessing the miRNAs under study in relation to these pathways, a plethora of 
associations are discovered. In colorectal cell lines miR-145 prevents the 
translocation of ß-catenin and PAK-4 (serine/threonine p21 activating kinase) into 
the nucleus by directly targeting catenin δ -1, resulting in  downregulation of c-Myc 
and Cyclin D through the canonical Wnt pathway (Yamada et al., 2013). MiR-145 
also acts to directly target PAK-4, eliciting downstream deregulation of the MAPK 
pathway via P-ERK (Wang et al., 2012). Furthermore, miR-145 is responsible for the 
p-53 mediated repression of c-Myc, a proto-oncogene activated by the Wnt and 
MAPK pathway (Sachdeva et al., 2009). EGF-R (epidermal growth factor receptor) 
initiated signalling also downregulates miR-145 via ERK1/2 in non-small cell lung 
cancer cells (Guo et al., 2014). The upregulation of miR-145 by TGF-ß1 in 
mesenchymal stem cells and TGFBR2 targeting by miR-145 in vascular smooth 
muscle cells possibly indicates a negative feedback regulatory role of miR-145 in 
TGF-ß signalling (Mayorga & Penn, 2012; Zhao et al., 2015).  
MiR-143 is implicated in the MAPK and Wnt pathways, whereby ubiquitous 
expression of the miRNA in cooperation with miR-145 targeted the ERK5/c-myc 
pathway and also the p68/p72/ß-catenin pathway in intestinal tumours of APCMin/+ 
mice (Takaoka et al., 2012). Notably, miR-143 and miR-145 are bicistronic cluster 
miRNAs transcribed from the same gene and are commonly reported to cooperate in 
regulating their targets. Moreover, they are regulated similarly as they are derived 
from the same transcript. The miR-143/145 cluster has been found to be suppressed 
by RREB1 (Ras responsive element (RRE) protein), a downstream effector of KRAS 
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in the MAPK pathway (Kent et al., 2013). Repression of the cluster miRNAs is 
dependent on the constitutively active form of KRAS found in CRC, therefore 
triggering all effectors in the signalling cascade. Interestingly, miR-145 and miR-143 
in their individual mature form, target RREB1 and KRAS respectively, forming an 
auto-regulation loop of the KRAS signalling pathway in CRC (Kent et al., 2010; Chen  
et al., 2009). Reminiscent to the relationship of miR-145 with TGF-ß, miR-143 is also 
induced by TGF-ß in non-small cell lung cancer and is found to target Smad3 
(Cheng et al., 2014). Furthermore, the miR-143/145 cluster is induced by TFG-ß and 
BMP4 (Bone morphogenetic protein 4) in vascular smooth muscle cells (VSMC) 
(Davis-Dusenbery et al., 2011). As a result of the induction of the miRNA cluster in 
VSMC, KLF4 is downregulated with miR-145 appearing to play a dominant role in 
targeting KLF4. KLF4 expression in turn however, negatively regulates the 
transcription of the miRNA cluster, substantiating an auto-regulation loop.  
MiR-133b, despite being less reported in cancer in comparison to miR-143/145, is 
involved in repressing the MAPK and PI3K/Akt signalling pathways through directly 
targeting EGFR (Epidermal growth factor receptor) in ovarian cancer (Liu & Li, 
2015). MiR-133b has been further implicated in the MAPK pathway whereby ERK1/2 
phosphorylation was inhibited by the expression of the miRNA perturbing the 
signalling pathway. Furthermore, in this same study it was determined that 
downregulation of the ERK1/2 signalling cascade was also affected by miR-133b 
targeting of FGFR1 (Fibroblast growth factor receptor 1) and PPP2CA/B (Protein 
phosphatase 2A catalytic subunit) 3’UTRs. These two genes participate in the Ras-
MAPK/ERK1/2 signalling cascade, with FGFR1 functioning as a ligand binding 
receptor and PPP2CA/B responsible for dephosphorylating molecules involved in 
critical cellular pathways (Feng et al., 2013). 
Despite the miRNAs being involved in distinct growth signalling cascades as 
described in the preceding paragraphs, their relation to other CRC pathways cannot 
be dismissed due to the evident cross talk between growth signalling pathways in 
CRC (Cheruku et al., 2015). 
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Genes involved in cell to cell and cell to ECM (extracellular matrix) interactions were 
also shown to be potential targets of the combined expression of miR-143, -145 and 
133b. This association is not surprising owing to the contribution of each miRNA to 
epithelial-mesynchymal transition, a vital step in the development of invasion and 
metastasis in cancer (Zhai et al., 2015; Lin et al., 2014; Hu et al., 2012; Hu et al., 
2014; Ren et al., 2014). Additionally, the significantly enriched pathways discussed 
above are also closely associated and interlinked in the regulation of EMT in cancer 
(Linsey & Langhans, 2014).  
The last enriched category of miRNA targets relates to neuron signalling and 
neurodegenerative disorders. Although this association is not within the scope of this 
dissertation, it cannot be overlooked that EGFR, which is integral to the ErbB, MAPK 
and PI3K signalling pathways and a target of miR-133b, has been known to be 
implicated in neuron survival and neurodegenerative disorders (Wagner et al., 2006; 
Bublil & Yarden, 2007). Furthermore, it has been reported that miRNA expression 
profiles in cancer have been found to be similar to the profiles in neurodegenerative 
disorders and the miRNAs are hypothesised to target pathways that are commonly 
deregulated between the two diseases, or alternatively by targeting gene subsets 
within each disease type (Du & Pertsemlidis, 2011; Saito & Saito, 2012). Although 
miR-133b has been reported to be downregulated in cancer, it has however also 
been reported to be repressed in mid-brain tissue in Parkinson’s disease (PD) 
patients. This involvement in PD was further supported by the finding that a negative 
feedback regulation loop exists between mir-133b and PitX3, a transcription factor 
that is involved in the regulation of midbrain dopaminergic neurons (Kim et al., 2007).  
3.4.3 Selection of potential miRNA targets for functional analysis 
 
Table 3.2 lists the shortlisted miRNA target genes that were curated and filtered 
according to the method described in Chapter 3.2. The top three ranked putative 
targets per miRNA are described below.   
With regards to miR-143, there were only six shortlisted predictions according to the 
curating methodology used here (Table 3.2). Of the six predicted targets, the first 
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(KRAS) and the third (BCL2) ranked targets have already been experimentally 
validated. KRAS, which is associated with CRC and MAPK KEGG pathways and 
ranked first according to the filtering used in this study, has the strongest association 
with CRC as an established oncogene activating the MAPK pathway (Tan & Du, 
2012). Between 35-45% of CRCs harbour KRAS mutations in codon 12 and 13 and 
therefore genotyping of KRAS in CRC patients has become a mandatory disease 
management tool due to the non-response to anti-EGFR antibody treatment in KRAS 
mutated CRC patients. KRAS has been determined to be a direct target for miR-143 
in CRC (Chen et al., 2009). In the study by Chen et al. (2009), the two conserved 
KRAS binding sites which have been predicted in the present study have been 
experimentally validated to bind to miR-143. The third non-conserved binding site 
demonstrated lower overall scoring compared to the conserved sites, but 
nevertheless cannot be dismissed as a putative binding site, as all three programs in 
this study were profoundly reliant on conservation and therefore bias in scoring may 
be an end result. While KRAS is already known to be a validated target of miR-143 
in CRC, for the purpose of the inclusion of a positive control, the KRAS target was 
selected for functional analysis.  
BCL2, an anti-apoptotic protein and ranked third in this study, is crucial in regulating 
cell death and is targeted by miR-143 in cervical cancer (Liu et al., 2011). It is not 
certain whether BCL2 targeting by miR-143 occurs in CRC as there is a lack of 
evidence of the protein being overexpressed (Biden et al., 1999; Ilyas et al., 1998). 
An inverse correlation of the protein and miR-143 is necessary to infer potential 
miRNA targeting.  
The second ranked putative target is PDGFRA (platelet derived growth factor 
receptor alpha polypeptide), a subunit of the PDGF receptor that is involved in 
activating growth signalling pathways such as Ras-MAPK and PI3K which are 
involved in several cancers, including CRC (Andrae et al., 2008; Heldin et al., 1998). 
In CRC, PDGFRA expression in association with PDGFRB is associated with lymph 
node metastasis and advanced disease and therefore increased expression in CRC 
would make the target attractive as a putative target of miR-143 (Wehler et al., 
2008).  
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MiR-145 is the most referenced miRNA hypothesised to be a tumour suppressor due 
to its widespread role in tumourigenesis. Of the 11 shortlisted potential targets for 
this miRNA, two have thus far been validated experimentally; SMAD3 and PPP3CA 
which are within the top three predicted targets in this study. SMAD3, the highest 
ranked putative target and a key player in the TGF-ß1 inflammatory pathway, is a 
direct target of miR-145 in nasopharyngeal cancer and in cystic fibrosis (Huang et 
al., 2015; Megiorni et al., 2013). In CRC, SMAD3 acts as a tumour suppressor, 
therefore an inverse correlation between miR-145 and the target cannot be 
determined (Fleming et al., 2013).  
FZD7 (Frizzled 7), a Wnt pathway receptor and the second highest ranked putative 
miR-145 target, was chosen as the potential target for further functional analysis. 
FZD7 has been dubbed as an emerging key player in Wnt pathway activation in 
several cancers (King et al., 2012). Strong oncogenic potential of FZD7 in activating 
the canonical Wnt pathway in CRC has also been reported and therefore this 
protein’s inverse correlation to miR-145 expression in CRC poses the gene as a 
reliable candidate for further functional analysis (Ueno et al., 2008). Target prediction 
in the present study yielded a single 7mer-m8 target site containing the seed region 
at position 518-524 of the FZD7 3’UTR. The prediction of this individual site by all 
three target prediction programs using differing algorithms potentially determines the 
likelihood of the site being a true target. This however would need to be verified 
experimentally using luciferase reporter assays.  
The third highest ranked potential target for miR-145 elucidated in this study is 
PPP3CA (protein phosphatase 3, catalytic subunit, alpha isozyme/Calcineurin 
alpha). PPP3CA also exhibits regulation by miR-145 in urothelial cancer cells 
(Ostenfeld et al., 2010). A role of PPP3CA in CRC however has not been clarified 
despite its involvement in Wnt and MAPK KEGG pathways and therefore was not 
considered in this study for further functional analysis.    
In considering miR-133b, a total of ten potential targets were shortlisted, of which 
four are experimentally validated targets (PPP2CA, PPP2CB, SP1 and FGFR1). 
PPP2CA and PPP2CB together form the protein phosphatase 2A catalytic subunit 
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PP2AC which is involved in the MAPK-ERK1/2 signalling cascade through 
dephosphorylating proteins within the signal pathway. Both individual genes have 
been found to be direct targets of miR-133b in myoblast cells together with FGFR1, a 
fibroblast growth factor receptor, which was also predicted here as a potential target 
for miR-133b, albeit only ranked at number 7 (Feng et al., 2013). In CRC, PP2AC 
seems to function as a tumour suppressor, whereby PP2AC is commonly inactivated 
in CRC and growth is inhibited upon PP2AC activation (Cristobal et al., 2014). 
Furthermore, this inactivity of PP2AC is attributed to hyper–phosphorylation of its 
sub-units and is associated with poor prognosis in CRC (Cristobal et al., 2014). The 
expression profile of PP2AC in CRC makes it an unlikely target of miR-143 in CRC.   
FBXW11 (F-box.WD repeat containing protein 11), also known as ßTrCP2 (beta-
Transducin repeat-containing protein) or HOS, is the third ranked potential target for 
miR-133b. This protein is part of the F-box protein family, exhibiting a 40 residue 
structural motif known as the F-box, which forms part of an E3 ubiquitin ligase 
complex SCF (SKP1-Cullin 1–F-box proteins) and is responsible for recognizing 
substrates targeted for post-translational ubiquitination and proteasomal degradation 
(Bielskiene et al., 2015). ßTrCP2 is involved in regulation of cell cycle checkpoints 
and several signal transduction pathways implicated in cancer (Fuchs et al., 2004).  
An important feature in the context of this study is ßTrCP2 involvement in 
proteasomal degradation of phosphorylated ß-catenin and subsequent regulation of 
the Wnt pathway (Voutsadakis, 2008). In CRC, elevated levels ßTrCP mRNA and 
protein was recognised in colorectal tumours compared to normal tissue and this 
increase in expression was significantly associated with ß-catenin activation 
(Ougolkov et al., 2004). Owing to the oncogenic potential of ßTrCP2/FBXW11 in 
CRC and particularly its involvement in the Wnt pathway, it was selected for further 
functional analysis.  
There were a few noteworthy observations from the shortlisted predicted targets in 
Table 3.2. Gli3, a protein involved in the Hedgehog signalling pathway and found to 
be overexpressed in CRC (Kang et al., 2012), was predicted as a potential target of 
miR-143 in this study. It has however been confirmed as a target of miR-133b in 
human Sertoli cells, promoting proliferation through the activation of Cyclin B1 and 
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Cyclin D1 in spermatogenesis regulation (Yoa et al., 2016). Sp1, a transcription 
factor exhibiting widespread regulation of several biological processes and proven 
vital in tumourigenesis, is a validated target for miR-133b and miR-145 in gastric 
cancer cells, as reported by Qui et al., 2014. However in this study, the Sp1 target 
has only been predicted as a potential target of miR-133b. Smad 3 is a downstream 
transcription factor of the TGF-ß signalling pathway and is phosphorylated by 
activated TGFBR1 to translocate into the nucleus to induce the expression of genes 
responsive to TGF-ß signalling (Xu & Pasche, 2007). Although SMAD3 was the 
highest ranked predicted target for miR-145 in this study, previous validation of 
SMAD3 targeting by miR-143 has recently been determined in non-small cell lung 
cancer (Cheng et al., 2014). It may be possible that as a cluster, these two miRNAs 
both target SMAD3 in regulating TGF-ß signalling.  
CSNK1G3, known as casein kinase 1, gamma 3, is responsible for phosphorylation 
of proteins involved in key CRC signal transduction pathways such as Wnt signalling 
(del Valle-Perez et al., 2011), and has been predicted as a potential common target 
for miR-143 and miR-133b in the present study, thus posing CSNK1G3 as an 
interesting target for future evaluation. 
3.4.4 Functional Analysis of selected potential miRNA targets 
 
KRAS protein was assessed in HET 1A cells transfected with Anti-miR™ 143 and 
compared to untransfected cells and experimental controls. The increase in 
fluorescence in the anti-miR-143 transfected cells, when compared to the 
untransfected cells was an expected response owing to the previously established 
targeting of KRAS by miR-143 (Chen et al., 2009). KRAS expression in the negative 
control and transfection control samples were comparable to the untransfected cells, 
indicating that the increase in KRAS expression in the cells transfected with anti-
miR-143 was related to the inhibition of miR-143. The observed increase in regions 
of cytoplasmic fluorescence, together with staining of the nuclear periphery is 
consistent with a cytoplasmic inhibition of KRAS translation following knockdown of 
miR-143.  Moreover, from these results it is suggested here that the trafficking of 
KRAS towards the cytosolic side of the cell membrane is also prevented. The 
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extension of KRAS from the nuclear periphery to the polar regions of cell is 
potentially indicative of KRAS transport to the plasma membrane. Transport of Ras 
proteins to the plasma membrane, reviewed by Hancock (2003), describes that 
KRAS is part of the RAS GTPase family of which cytosolic modification of a CAAX 
motif in the C-terminal of the protein is crucial in targeting of the plasma membrane. 
KRAS is post-translationally modified in the cytosol by prenylation which adds a 
farsenyl group to the cysteine residue within the CAAX motif at the carboxy terminal. 
On the cytosolic facing endoplasmic reticulum, the farsenylated C-terminal is then 
cleaved of the AAX from the CAAX motif by a protease known as Rce. 
Subsequently, the remaining cysteine residue containing a farsenyl group is 
methylated by the methyltransferase Icmt. The resulting C-terminal is hydrophobic, 
while the rest of the molecule is hydrophilic, making the KRAS protein amenable to 
plasma membrane integration.  It has been determined however that not only is the 
post-translationally modified KRAS necessary for targeting the plasma-membrane 
but also for targeting of the endomembrane (Choy et al., 1999). The endomembrane 
includes several membranous structures and organelles (nuclear membrane, 
endoplasmic reticulum, Golgi apparatus, lysosomes and vesicles) that function to 
transport lipids and proteins within the cell. The cytoplasmic pattern of KRAS 
expression observed here upon miR-143 inhibition is supportive of KRAS trafficking 
from the nucleus to the plasma membrane via the endomembrane.   
 
Frizzled-7 (FZD7) protein expression was assessed by immunofluorescence after 
transfection of HET-1A cells with a miR-145 inhibitor. FZD7 was found here to be 
minimally expressed in untransfected HET-1A cells, this being consistent with the 
report by King et al. (2012) of limited FZD7 expression in normal cells. In contrast 
however, a marked expression of FZD7 protein was reported here in the Anti-miR-
145 transfected cells. The increased fluorescence signal was particularly evident in 
the nucleus and nuclear periphery, potentially indicating an increase in FZD7 protein 
translation and processing at the endoplasmic reticulum, before being transported to 
the plasma membrane, where it functions as a seven-pass transmembrane receptor 
to strongly activate the Wnt pathway. 
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In this study an inverse correlation has been demonstrated between miR-145 and 
FZD7 through inhibition of miR-145 and consequent upregulation of FZD7 protein. 
This inverse correlation was similarly described in the ACHN renal cell carcinoma 
cell line, whereby transfection with a miR-145 precursor, which essentially induces 
cellular miR-145 overexpression, resulted in significant downregulation of FZD7 
protein (Lu et al., 2014). The inverse correlations with FZD7 protein noted upon 
inhibition and overexpression of miR-145 provides circumstantial evidence of direct 
targeting of FZD7 by miR-145. An earlier study by Zhang et al., in 2011 had 
assessed direct targeting of miR-145 to a predicted binding site in FZD7 3’UTR (518-
524) in 293T cells via luciferase reporter assay. The predicted binding site within 
FZD7 3’UTR was cloned into the Xba1 site of a pGL3 reporter vector downstream of 
the luciferase reporter gene and co-transfected into 293T cells with either a miR-145 
precursor or anti-miR-145. Notably, the predicted binding site used in Zhang et al’s 
(2008) study matched the site predicted in the present research, with the seed region 
being at position 518-524 of FZD7 3’UTR. However, luciferase activity was 
unchanged between the cells transfected with either the miR-145 inhibitor or the 
miR-145 precursor, rejecting the hypothesis of miR-145 targeting this particular seed 
region. An intriguing observation however is that despite FZD7 expression being 
limited and almost absent in normal cells (see King et al., 2012), mRNA for the gene 
has been previously detected in human foetal kidney cells (Sagara et al., 1998). It is 
plausible that the proteomic output of FZD7 in human embryonic 293T kidney cells is 
less dependent on miR-145 than in other cells such as CRC cells. This however 
would require validation with a luciferase reporter assay in a CRC cell line.    
 
FBXW11/ß-TRCP2 expression was detected after anti-miR™ 133b transfection into 
HET-1A cells. Compared to the untransfected and control cells, FBXW11/ß-TRCP2 
displayed clear upregulation, with concentrated nuclear and peri-nuclear expression, 
while retaining expression in the cytoplasmic region. In the control experiments 
FBXW11/ ß-TRCP2 was very weakly associated with the nucleus. 
 
The inverse correlation recognised between miR-133b and FBXW11/ß-TRCP2 
corroborates with a miRNA-target relationship. FBXW11/β-TrCP2 is known to 
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localise to both the cytosol and the cell nucleus, which is consistent with expression 
of FBXW11/ß-TRCP2 reported here with miR-133b inhibition. It is relevant to note 
here that there are two cellular splice variants of FBXW11/ß-TRCP2 that vary in 
subcellular localization, with the βTrCP2γ variant residing exclusively in the cytosol 
and βTrCP2β being solely detectable in the nucleus (Putters et al., 2011). 
Interestingly, ß-TRCP has also been found to accumulate in the nuclei of cancer 
cells (Ougolkov et al., 2004). It is plausible here that miR-133b targets the βTrCP2β 
variant and therefore upon downregulation of miR-133b, βTrCP2β variant protein 
expression could be induced in the nucleus. In the present study, since the antibody 
used could not discriminate between ß-TRCP2 splice variants, this will need further 
validation.  
 
Notably, ß-catenin, a substrate of the E3 ubiquitin ligase containing ß-TRCP2, is 
commonly overexpressed in the nucleus of CRCcells (Brabletz et al., 1998). It has 
also been shown that nuclear APC (adenomatous polyposis coli tumour-suppressor 
gene) and ß-TRCP bind to Wnt regulatory elements and regulate the transcriptional 
activity of ß-catenin in a cyclical manner, this by either inducing the transcription of 
Wnt responsive genes, acting to recruit ß-catenin transcriptional coactivators or by 
reducing transcription with the recruitment of co-repressors to the promoter regions 
of the Wnt responsive genes (Willert & Jones, 2006). The important role of ß-TRCP2 
as a key regulator of ß-catenin stabilization and the expression of Wnt responsive 
genes makes the protein amenable to deregulation in CRC, and as supported by the 
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CRC represents a large percentage of worldwide cancer incidence and mortality, 
therefore substantiating the importance of understanding the genetic and epigenetic 
mechanisms underlying tumourigenesis in these cells, which will ultimately allow for 
the design of innovative and effective diagnostic and therapeutic interventions to 
reduce the disease burden. Deregulation of miR-145, -143 and -133b in CRC 
indicates these small molecules as key drivers of tumourigenesis. Analysis of their 
regulation and biological targets will provide valuable information for CRC 
therapeutics. These miRNAs also have potential as predictive markers and 
therapeutic targets.  
4.1.1 Epigenetic regulation of miRNAs and cross talk between epigenetic 
factors 
The first part of this study aimed at identifying potential epigenetic regulation, by 
means of histone deacetylase inhibition and DNA demethylation, of these three 
putative suppressor miRNAs, in both early and late stage CRC cell lines originally 
derived from CRC patients. It was determined that all three putative tumour 
suppressor miRNAs are more susceptible to regulation by DNA demethylation in the 
late stage DLD1 (Dukes’ stage C) CRC cells than the early stage SW1116 (Dukes’ 
stage A) cells, these findings being consistent with published data suggesting that 
DNA hypermethylation is accumulated during CRC carcinogenesis process, with late 
Dukes’ stages showing higher levels of DNA hypermethylation (Frigola et al., 2005)   
Conversely, histone deacetylation  would seem to play a minimal role in the 
regulation of miRNAs in the late stage DLD1 CRC cells, since the miRNAs were 
susceptible to histone deacetylation regulation only in early stage SW1116 cells. The 
non-response of miRNA-143, -145 and -133b to HDACi (TSA) treatment was an 
unexpected finding.  
  
  116 
 
 
At the outset the focus in this study was to detect tumour stage-specific differences 
in epigenetic regulation of each miRNA. However the results were justified rather by 
the genotypic differences (MSI vs MSS/CIN) between the two cell lines than by their 
particular Dukes’ stage. As the development of MSI and MSS/CIN tumours occur 
through separate carcinogenesis pathways wherein the accumulation of genetic and 
epigenetic alterations differ, it is expected that the miRNA levels differ between the 
two genotypes and are regulated through different mechanisms which ultimately will 
have an implication on the use of epigenetic therapy in CRC. Additional studies 
utilizing more MSI and MSS CRC cell lines will need to confirm the variances in 
epigenetic regulation of miR-143, -145 and 133b.  
  
MiRNAs have also been found to be involved in epigenetic feedback loops with other 
epigenetic machinery and these miRNAs are referenced as epi-miRNAs. It is 
postulated that these double negative feedback loops that exist between epigenetic 
entities and miRNAs are key regulatory circuits in the cell which are crucial to cellular 
decision making (Osella et al., 2014). Of particular interest in this study, miR-143 
was reported to target DNMT3a, a DNA methyltransferase, directly in CRC (Ng et al., 
2009). It has thereafter been determined that miR-143 is hypermethylated by the 
increase in DNMT3 expression (Zhang et al., 2016). Due to the polycistronic nature 
of the miR-143/145 cluster, it is not surprising that a feedback loop is also found 
between miR-145 and DNMT3b, wherein miR-145 directly targets DNMT3b by 
binding to its 3’UTR and in turn, DNMT3b is responsible for downregulation of miR-
145 via CpG island promoter methylation (Xue et al., 2015). An interesting finding in 
this particular study was that this double negative feedback loop between miR-145 
and DNMT3b had sensitised prostate cancer cells to radiation therapy. With regards 
to histone acetylation, miR-145 mimics were shown to repress HDAC2 in 
hepatocellular carcinomas and has been validated as a direct target (Noh et al., 
2013). Class I HDACS (HDAC1, 2 and 3) are also upregulated CRC and have a 
prognostic value as their increased expression relates to poor survival outcomes 
(Weichert et al., 2008). While these are only a few examples that are relevant to this 
present study, there is however growing numbers of examples of epi-miRNAs being 
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discovered which form double negative feedback loops with epigenetic machinery. A 
model of interplay between epigenetic regulators is depicted in Figure 4.1. In 
determining the mechanisms of regulation of miRNA, the existence of double 
negative feedback loops between the regulator and miRNA will be an important 












Figure 4.1: Interplay of epigenetic regulation.  miRNAs 
commonly exist in double negative feedback loops with 
epigenetic machinery. miRNAs regulate the activity of 
DNMTs and HDACs and in turn the expression of miRNAs 
are regulated through DNA methylation and chromatin 
remodelling (Adapted from Chuang & Jones, 2007). 
4.1.2 Computational target prediction as a catalyst in determining miRNA 
functions 
The target genes of miRNA-145, -143 and -133b are putative oncogenes that could 
pose as therapeutic targets for CRC therapy. By using a strategic computational 
approach, this study aimed to identify the role of these miRNAs in colorectal 
carcinogenesis by analysing computationally predicted targets through TargetScan, 
PicTar and DIANA MicroT v3.0 algortihms. 
Targets for miR-143, -145 and -133b predicted from all three bioinformatic tools were 
enriched for KEGG pathways using the DIANA mirPATH v1 algorithm with the 
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Cell-cell and cell-ECM interactions and Neuron signalling. The combined list of 
potential targets were used as it was hypothesised that if all three miRNAs are 
downregulated in CRC, that they would together affect CRC related pathways.  
References of each miRNA to these categories had provided initial confidence in the 
extensive list of targets received (described in Chapter 3.4.2). By selecting the 
KEGG pathways associated to CRC related pathways and only those targets that 
were commonly predicted by all three target prediction programs, the list was 
narrowed down significantly for each miRNA. The Wnt signalling KEGG pathway 
was found to be most enriched, followed by TGF-ß signalling pathway, “Colorectal 
cancer”, MAPK signalling pathway and Notch signalling pathway. Cross-talk between 
these pathways is characteristically associated with CRC carcinogenesis (Cheruku 
et al., 2015). The ability of the bioinformatics tools selected in this study to accurately 
predict pathways of involvement in CRC demonstrated credibility of the methodology 
devised to filter the extensive list of predicted targets. Further confidence in this 
method was provided when it was determined that out of the six shortlisted targets 
for miR-143 there were two that have been previously validated experimentally. For 
miR-145, two out of ten have been validated and for miR-133b four out of the ten 
shortlisted targets have previously been proven as targets of the miRNA. Elected 
targets for further functional analysis were based on literature analysis of expression 
patterns in CRC. Inverse correlations between the miRNA and predicted target in 
CRC were determined for KRAS (miR-143), FZD7 (miR-145) and FBXW11/ß-TrCP2 
(133b). Immunofluorescence staining with KRAS, FZD7 and FBXW11/ß-TrCP2 
antibodies after transfection with anti-miR-143, -145 and -133b, respectively, 
demonstrated a positive corroboration of miRNA-target relationships for each pair 
and therefore potential therapeutic targets in CRC. Figure 4.2 illustrates the 
signalling pathways and their cross talk contributing to CRCmetastasis, highlighting 
in addition the miRNA targets assessed in this study.   
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Figure 4.2: Colorectal cancer signalling pathways. Wnt, MAPK and 
TGF-beta signalling pathways are clear drivers of CRC 
tumourigenesis. The position of FZD7, KRAS and FBXW11 in the 
CRC metastatic pathway is indicted by red stars. Qiagen, 2013 
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The use of bioinformatics in the field of miRNA target prediction has exponentially 
increased over the last few years. The algorithms being developed now combine 
complex mathematical models to the principals already known regarding miRNA-
target recognition and to expression data to provide reliable outputs (Banwait & 
Bastola, 2015).  The majority of these new algorithms utilise machine learning, the 
science of allowing a computer to learn and perform functions without being explicitly 
programmed (Samuel et al., 1959). Machine learning methods are an artificial 
intelligence-like approach to miRNA target prediction, which involves the 
development of complex algorithms using sets of validated target datasets and 
training data from microarrays as templates, in determining binding characteristics or 
statistically significant features. It then uses the learned characteristics or significant 
features to determine the maximum likelihood of a miRNA binding to a putative 
target region (Peterson et al., 2014). There are several machine learning 
applications used to develop algorithms for prediction of miRNAs; including for 
example, Support Vector Machines, NaÏve Bayes Classifier and Hidden Markov 
Models being the most commonly used in miRNA target prediction computational 
tools.   
Machine learning methods are fast becoming a preferable method of prediction. 
Firstly, these supervised learning programs boast higher sensitivity and specificity 
when compared to programs that rely largely on sequence conservation, which was 
initially preferred as it reduced the number of false positives (Peterson et al., 2014). 
Programs that rely on conservation are not able to reliably predict non-conserved 
targets between species, which would result in a bias in the prediction results as 
would be the case in this study. In this case miRNA targets that have evolved 
through selection events would not be identified. Furthermore, as these models 
which are supervised learning systems requires training by experimentally validated 
datasets, the reliability of the program improves as more validated datasets are 
available. This essentially means that the predictive power of the programs will only 
increase as more targets are validated and as these data sets become available.  
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Despite miRNAs being discovered over two decades ago, identification of miRNA 
targets is still in an infant stage and therefore the establishment of more validated 
targets only enhances our ability to predict more targets in future. This clearly 
justifies the need to identify miRNA targets that are not currently validated and 
therefore provide us with a deeper understanding of the miRNA footprints in a cell.  
4.2 Future Considerations 
 
In this study, regulation patterns of miR-145, -143 and -133b in Dukes’ stages A 
versus C and also MSI versus MSS genotypes of CRC have been established. 
These results however could not determine whether these changes in miRNA 
expression were due to the direct effect of CpG promoter hypermethylation or the 
presence of acetylated histones and therefore indirect effects on the miRNAs cannot 
be discounted. It will be of relevance to confirm the findings by performing bisulfite 
sequence analysis and qPCR to assess the existence of methylated CpG islands in 
promoter regions of the miRNAs. Additionally, to characterise the change in miRNA 
expression as a function of histone modification by acetylation, it will be necessary to 
perform chromatin immunoprecipitation (ChiP) assays.  
Conducting the analysis in various MSI and MSS CRC cells will also prove valuable 
in determining the miRNA regulation mechanisms between both genotypes. Since 
these genotypes progress through separate carcinogenesis pathways, the 
differences in epigenetic regulation of miRNAs would affect the treatment 
optimisation strategies for each genotype.   
5-Aza-2’-C and TSA were used as single agents in this study. However, there have 
been reports of synergistic activity between TSA and 5-Aza-2’-C in reactivating 
silenced genes and inhibiting cell proliferation (Chai et al., 2008; Cecconi et al., 
2009). The influence of synergistic epigenetic treatment on the expression of miR-
143, -145 and -133b in CRC could prove valuable as a potential therapeutic 
intervention.  
MiRNA prediction methodology used in this study was successful in shortlisting 
candidate targets, some of which have already been validated as direct targets of the 
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miRNAs. However there were limitations in the methods, involving the use of older 
miRNA datasets through the use of PicTar, a potential conservation bias due to the 
use of programs that all are reliant upon mapping to orthologous sequences and the 
inability to detect synergistic target sites, due to the scoring of individual sites by the 
DIANA MicroT program.  These would need to be considered in downstream 
functional analysis assays and alleviated through the use of new target prediction 
algorithms that consider updated miRNA-target information, the ability to detect non-
conserved and synergistic sites.  
KRAS, FZD7 and FBXW11/ß-TrCP2 proteomic expression as evaluated by 
microscopy increased upon miR-143, -145 and -133b inhibition, respectively. While 
this provides evidence of a miRNA-target relationship, it will be relevant to detect the 
mRNA expression of each gene using qPCR to confirm the absence of translational 
repression upon miRNA inhibition. Finally, to confirm the direct targeting of the 
miRNAs to each target, the 3’UTR of each gene containing the target sites predicted 
in the present study should be cloned into a reporter plasmid downstream of a 
luciferase or green fluorescent protein (GFP) open reading frame. Once the 
recombinant plasmid is transiently transfected into a neutral host cell together with 
the associated miRNA, the levels of fluorescence should be assessed to determine 
direct targeting of the predicted site by each miRNA. Alternatively, Western blotting 
could be utilised to detect changes in protein expression levels in nuclear and 
cytoplasmic compartments, respectively. Ultimately, detection of the target protein 
levels and the miRNAs in CRC and matched normal tissue samples may be of value.    
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Appendix B – Reagent Constituents 
 
10%v/v FBS/DMEM:F12 
5mL fetal bovine serum (Invitrogen) 
45mL DMEM:F12 (Invitrogen) 
100μL 10000U penicillin/mL/10 000ugstreptomycin/mL (Lonza) 
 
2%v/v FBS/DMEM:F12 
1mL fetal bovine serum (Invitrogen) 
49mL DMEM:F12 (Invitrogen) 
100μL 10000U penicillin/mL/10 000ugstreptomycin/mL (Lonza) 
 
BEBM (Bronchial Epithelial Basal Medium)  
50mL of BEBM (Lonza)  
200µL Bovine Pituitary Extract,  
50µL Insulin, 
50µL hydrocortisone,  
50µL GA-1000 (Gentamycin – Amphotericin),  
50µL Retinoic Acid,  
50µL Epinephrine,  
50µL Transferrin,  
50µL Triiodothyronine and  
50µL human EGF (epidermal growth factor). 
 
200mL PBS 




48.5mL PBS (Sigma-Aldrich) 
1.5mL Formaldehyde (Univar) 
  




0.5g bovine serum albumin (Sigma-Aldrich) 
100mL PBS (Sigma-Aldrich) 
 
0.5%v/v BSA/PBS/Triton X 
25mL 0.5%v/v BSA/PBS (Sigma-Aldrich) 
125μL Triton X (Lonza) 
 
Primary antibody 1:100 
1μL primary antibody (KRAS, FZD7 and ß-TrCP2) 
99μL 0.5%v/v BSA/PBS 
 
 KRAS (F234) Mouse monoclonal IgG 200ug/mL Santa Cruz 
Biotechnologies Cat. no. sc-30 
 FZD7 (F-13) Goat polyclonal IgG 200ug/mL Santa Cruz 
Biotechnologies Cat. no. sc-31063 
 ß-TrCP (E-20) Goat polyclonal IgG 200ug/mL Santa Cruz 
Biotechnologies Cat. no. sc-9599 
 
Secondary antibody 1:200 
1μL secondary antibody (Santa-Cruz) 
199μL 0.5%v/v BSA/PBS 
 
 Alexa Fluor® 568 conjugated donkey anti goat 0.5mL, Life 
Technologies 
 Alexa Fluor® 568 conjugated donkey anti mouse 0.5mL, Life 
Technologies 
DAPI 1:10 000 
1μL DAPI (Boehringer Mannheim) 
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9 999μL/~10mL PBS 
 
Microscope and software details 
 Olympus IX71- inverted microscope with epifluorescence 
 Software: analySIS FIVE, Olympus Soft Imaging 
 Systems, Germany 
 
 Zeiss Laser Scanning Microscope 
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Appendix C - The 2-ΔΔCt method 
 
 
The 2-ΔΔCt method was used to assess relative gene expression in this study 
(Livak and Schmittgen, 2001). The Ct of the target gene was first normalised to 
that of the reference gene (in this case 18S rRNA) for both test and control 
samples following equations: 
 Ct(miR)  Ct (miR - treated)  C(18s rRNA - treated)   
Ct(control) Ct (miR - control)  Ct (18s rRNA - control)   
The CT of the miR sample was then normalised to the CT of the control as seen 
below:  
Ct  Ct(miR) C(control)   
As a result, the ratio of the target gene in the test sample to the calibrator 
sample is found, which is normalised to the reference gene. All treated sample 
results are relative to the untreated samples. The expression ratio can be 
calculated as below: 
 Normalised target gene expression = 2(-Ct) 
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Appendix D – KEGG pathway enrichment per miRNA 
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Appendix E – Conservation of miRNA target sites 
 
miR-143 
Figure A4: Conservation of miR-143 binding site in KRAS 
across 15 species. (TargetScan 5.1) 
miR-145 
Figure A5: Conservation of miR-145 binding site in FZD7 
across 14 species. (TargetScan 5.1) 
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miR-133b 
Figure A6: Conservation of miR-133b binding site in FBXW11 

























Appendix F – Turnitin Report 
 
